The National Genomics Research and Healthcare Knowledgebase

Amendment to the 100,000 Genomes Project Protocol v4

May 2019
Issued and approved by the Chief Scientist for Genomics England

© Genomics England Limited 2018
About this document

This document sets out the protocol for the further development of the 100,000 Genomes Project, and the inclusion of the research component of genomic data (up to the level of whole genome sequencing) as part of the future NHS-commissioned Genomic Medicine Service (NHS GMS). Until the NHS GMS is operational, a transition will be expected between the versions (v4 and 5) of the Protocol.

Outlined are the interfaces, the new elements and their impacts on patients, and the principles and standards established the 100,000 Genomes Project’s inception. It details the patient and clinical benefits, the scientific and transformational objectives, the implementation strategy, as well as the ethical and governance frameworks required for the research element of this Project.

Procedures for the diagnostic genomic laboratory services and clinical care offered by the NHS Genomic Medicine Service sit outside the scope of this document and will be defined by NHS England under established governance and accountability responsibilities.

For more information please visit www.genomicsengland.co.uk


With input from a Northern Ireland perspective from:
Shane McKee, Anne Moffatt, Julie McCarroll

With input from Welsh representatives:
Iris Egner, Julian Sampson, Sharon Whatley

With international and national peer review from:
The Genomics England Rare Disease, Cancer and Sequencing and Annotation Working Groups, the Ethics Advisory Committee, the Science Advisory Committee, and NHS England.

NOTE: Health and Social Care (HSC) in Northern Ireland (HSCNI) is the designation of the publicly funded services providing public health and social care services in Northern Ireland. HSC is delivered by a number of organisations including the Public Health Agency (PHA) and a number of health and social care trusts (HSC Trusts). Where the term “NHS” is used to refer to the National Health Service, where applicable this should be regarded as including HSCNI, unless otherwise stated.

NOTE: National Health Service Wales is the designation of the publicly funded services providing public health and social care services in Wales. Wales NHS is delivered by a number of health boards and the Health and Care Research Wales. Where the term “NHS” is used to refer to the National Health Service, where applicable this should be regarded as including NHS Wales unless otherwise stated.
Contents

1 Summary and background ......................................................................................... 6
   1.1 History of the Project .......................................................................................... 6
   1.2 Aims of the Project ............................................................................................ 7
   1.3 Genomics England and Partners ........................................................................ 8
   1.4 NHS Genomics Medicine Centres (GMCs) - 2015 to 2018 .............................. 8
   1.5 The NHS Genomic Medicine Service (NHS GMS) - 2018 onwards .................. 9
   1.6 Genomic testing including whole genome sequencing (WGS) ........................... 10
   1.7 Key differences from previous Protocol versions .............................................. 10
   1.8 NHS GMS-related impacts to potential participants ......................................... 11

2 The structure of the Programme ............................................................................. 12
   2.1 Beyond 100,000 Genomes (2018 onwards) ..................................................... 12
      2.1.1 The Rare Disease Programme .................................................................... 12
      2.1.2 The Cancer Programme .......................................................................... 16
   2.2 The Genomics England Infectious Disease partnership with Public Health England ........................................................................................................ 21
   2.3 Sample size considerations for research in rare disease and cancer ................... 21
      2.3.1 Declaring significance ............................................................................... 24
      2.3.2 Variation in gene size and mutation rate ...................................................... 24
      2.3.3 Genetic architecture, and discovering genes vs solving diseases .............. 24

3 Opportunities to extend beyond the primary phenotypes ..................................... 26
   3.1 Opportunities to extend beyond rare diseases, cancer and infection ............... 26
      3.1.1 Lifelong electronic health record linkage ..................................................... 26
      3.1.2 NHS and public health registry data linkage ................................................. 26
   3.2 Opportunities beyond whole genome sequencing ............................................ 27
   3.3 Opportunities for recruitment beyond the NHS GMS/clinical services ............ 27

4 The Genomics England Clinical Interpretation Partnership (GeCIP) ......................... 30
   4.1 The route by which researchers add value to GeCIP ......................................... 31
   4.2 The route for those who contribute patients and data from the NHS to add value to GeCIP ........................................................................................................ 32
   4.3 Establishing and working within the Clinical Interpretation Partnership ........... 32
   4.4 Accessing data as a Genomics England GeCIP Member ................................... 35
   4.5 The commitment of all data generated to the Genomics England Knowledge Base ........................................................................................................ 36
   4.6 GeCIP contribution to interpretation, validation and regulation of findings ........ 37
   4.7 Overarching GeCIP management and governance ............................................ 37

5 Feedback for participants ....................................................................................... 38
   5.1 Enhanced interpretation and handling of findings from the research environment ........................................................................................................ 38
   5.2 Policy for main findings, secondary findings, and incidental findings, and feedback to clinicians and patients ................................................................. 38
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme delivery and management</td>
<td>44</td>
</tr>
<tr>
<td>6.1 Project management</td>
<td>44</td>
</tr>
<tr>
<td>Informatics architecture</td>
<td>45</td>
</tr>
<tr>
<td>7.1 Information governance and security</td>
<td>45</td>
</tr>
<tr>
<td>7.2 Data access, sharing and acceptable uses of information from participants</td>
<td>47</td>
</tr>
<tr>
<td>7.3 Partnerships to ensure patient recruitment, sample and data acquisition</td>
<td>48</td>
</tr>
<tr>
<td>7.4 NHS England requirements and specifications – 100,000 Genomes Project and NHS GMS</td>
<td>48</td>
</tr>
<tr>
<td>7.4.1 NHS Genomic Medicine Centres (GMCs)</td>
<td>48</td>
</tr>
<tr>
<td>7.5 NHS England requirements and specifications – Genomic Medicine Service</td>
<td>48</td>
</tr>
<tr>
<td>7.5.1 Sample and DNA acquisition and logistics for NHS Genomic Medicine Service</td>
<td>49</td>
</tr>
<tr>
<td>7.5.2 Labelling of samples</td>
<td>49</td>
</tr>
<tr>
<td>7.5.3 DNA delivery to sequencer (logistics)</td>
<td>49</td>
</tr>
<tr>
<td>7.5.4 Sample and DNA acquisition and logistics for WGS</td>
<td>49</td>
</tr>
<tr>
<td>7.5.5 Key Performance Indicators (KPIs)</td>
<td>50</td>
</tr>
<tr>
<td>7.5.6 Data from sample acquisition site</td>
<td>50</td>
</tr>
<tr>
<td>7.5.7 Data from national NHS and other sources</td>
<td>50</td>
</tr>
<tr>
<td>Genomics England data access and acceptable uses</td>
<td>51</td>
</tr>
<tr>
<td>8.1 Users of the Project data</td>
<td>51</td>
</tr>
<tr>
<td>8.1.1 Patient access</td>
<td>51</td>
</tr>
<tr>
<td>8.1.2 NHS healthcare teams</td>
<td>51</td>
</tr>
<tr>
<td>8.1.3 Academic researchers and trainees</td>
<td>51</td>
</tr>
<tr>
<td>8.1.4 Commercial researchers and Industry engagement</td>
<td>51</td>
</tr>
<tr>
<td>8.2 Data access and sharing for the Project</td>
<td>51</td>
</tr>
<tr>
<td>8.2.1 Data sharing requirement</td>
<td>52</td>
</tr>
<tr>
<td>8.2.2 Access to service data</td>
<td>53</td>
</tr>
<tr>
<td>8.2.3 Corporate data sharing</td>
<td>53</td>
</tr>
<tr>
<td>8.3 Acceptable research uses</td>
<td>54</td>
</tr>
<tr>
<td>8.3.1 Types of purposes</td>
<td>54</td>
</tr>
<tr>
<td>8.3.2 Uses that the Project will decline</td>
<td>55</td>
</tr>
<tr>
<td>Genomics England data ownership and intellectual property</td>
<td>56</td>
</tr>
<tr>
<td>9.1 Genomics England publication policy</td>
<td>56</td>
</tr>
<tr>
<td>Consent</td>
<td>57</td>
</tr>
<tr>
<td>10.1 The process for consent in the Project</td>
<td>57</td>
</tr>
<tr>
<td>10.1.1 The consent form and patient information literature</td>
<td>59</td>
</tr>
<tr>
<td>10.1.2 Giving consent face-to-face</td>
<td>60</td>
</tr>
<tr>
<td>10.1.3 Giving consent at a requested home visit</td>
<td>60</td>
</tr>
<tr>
<td>10.1.4 Giving consent by post or email</td>
<td>60</td>
</tr>
<tr>
<td>10.1.5 Participants aged 16-18 years</td>
<td>61</td>
</tr>
<tr>
<td>10.1.6 Participants under the age of 16 years</td>
<td>61</td>
</tr>
<tr>
<td>10.1.7 Seeking consent where participation relates to a health emergency</td>
<td>62</td>
</tr>
<tr>
<td>10.1.8 Seeking consent to use samples and information regarding a person who is deceased</td>
<td>66</td>
</tr>
</tbody>
</table>
10.2  The Process for withdrawing from the Project................................................................................. 71
10.3  Personal insurance and the participants in 100,000 Genomes Project............................................. 74

11  Communications, stakeholder engagement and patient and public involvement........ 76
11.1  Communications strategy and governance arrangements.............................................................. 76
11.2  Communications and stakeholder engagement plan....................................................................... 76
   11.2.1  The Genomics Conversation ............................................................................................. 76
11.3  Genomics England research projects – seeking the views of patients and the public ............ 77
11.4  The National Participant Panel......................................................................................................... 77

12  Appendices........................................................................................................................................ 78
   Appendix 1  |  List of Abbreviations........................................................................................................ 78
   Appendix 2  |  WGS Sample Requirements .............................................................................................. 79
   Appendix 3  |  Genomics England Governance and Committees................................................................. 82
   Appendix 5  |  Letter of Insurance............................................................................................................... 84
   Appendix 6  |  Consent Process Flows........................................................................................................... 86
1 Summary and background
1 Summary and background

1.1 History of the Project

In December 2012, the then UK Prime Minister (David Cameron) announced as part of the UK Government’s Life Sciences Strategy, a programme of whole genome sequencing (WGS) known as the ‘100,000 Genomes Project’ (the Project).

The principal objective of the Project was to sequence 100,000 genomes from patients with cancer, rare disorders, and infectious disease. In addition, the Project’s aim is to link the sequenced data to a standardised, extensible account of diagnosis, treatment, and outcomes.

The Project was designed to produce new capability and capacity for the application of whole genome sequencing application in routine clinical care, to transform both the NHS and clinical genomics research.

In 2013, the Chief Medical Officer for England (Professor Dame Sally Davies) established a Strategic Priorities Working Group and recommended three main areas where the introduction of genomic technology would have the greatest benefit for patient health:

i. Rare diseases
ii. Certain cancers
iii. Infectious diseases

Established by the Department of Health and Social Care, ‘Genomics England’ was announced as the organisation responsible for delivering the Project by the Secretary of State for Health (Jeremy Hunt) during the NHS 65th Anniversary Celebrations in July 2013.

The Project quickly established a secure infrastructure for the protection and analysis of all clinical and genomic data. This environment was made available for approved academic and industrial research purposes, including contributing members of clinical organisations from the NHS.

The Chief Medical Officer’s July 2017 report, ‘Generation Genome,’ recommended the establishment of a National Genomics Board to oversee the integrated development of genomic services and research in England and across the UK. In preparation for the next phase of the Project, and the application of whole genome sequencing as part of a commissioned NHS service in England, a number of NHS transition groups were set up by NHS England to identify appropriate commissioning strategies for genomic testing, including both WGS and non WGS genomic testing.

In 2018, the Project is expected to complete the sequencing target of 100,000 genomes. The Project will transition to where the main source of recruitment, sample and data acquisition, and mechanism for return of results will be via the NHS Genomic Medicine Service (NHS GMS).

This will offer patients the dual opportunity of routine clinical care alongside the choice to participate in research spanning across all genomic tests within the NHS. This builds on the research infrastructure created by Genomics England to provide a national standardised approach to genomic medicine in the NHS, sitting alongside the continued research offer that is the focus of this
Routine care will follow care pathways defined by NHS England and are not covered in this document.

1.2 Aims of the Project

The research aims of the project continue but have evolved to encompass a research opportunity for patients across all genomic tests undertaken by the NHS GMS. These aims are:

- **Patient benefit**
  - Provide clinical diagnoses with research opportunities to participants across all genomic and multi-omic testing in the NHS
  - Discovery of new causes of disease, offer tailored choice of therapies to create the best outcomes, and prime new or more effective treatments for NHS patients

- **New scientific insights and discoveries**
  - Create a database of all genomic data, including all genomic and omics tests. This will comprise of, but not be limited to: single gene tests, targeted gene sequencing, coding region sequencing (1% of your genome that codes for proteins – the exome), whole genome sequences and other multi-omic tests. This dataset will be based on the offer of research participation to all individuals being offered a genomic test in the NHS or other cohorts.
  - Information linked to continually-updated, long-term patient health and personal information to aid analysis by researchers.

- **Accelerate the uptake of genomic medicine in the NHS**
  - Work with NHS England and other partners to deliver a scalable NHS GMS including all genomic tests and an informatics platform to enable these services to be made widely available for NHS patients.
  - Through the international coalition of research intellects known as the Genomics England Clinical Interpretation Partnership (GeCIP):
    - Create a mechanism for research to continually improve the accuracy and reliability of information fed back to patients
    - Add to knowledge of the genetic basis of disease

- **Stimulate and enhance UK industry and investment**
  - Provide access to this unique research data resource to industry for the purpose of developing new knowledge, methods of analysis, medicines, diagnostics and devices.

- **Increase public knowledge and support for genomic medicine**
  - Deliver an ethical and transparent programme
  - Retain patient and public trust and confidence
  - Work with a range of partners to increase knowledge of genomics
1.3 Genomics England and Partners
The Department of Health and Social Care has established Genomics England as a wholly owned, limited company to provide the informatics infrastructure, bioinformatics pipeline and research functions of the evolving Project. Here we focus on the research dataset derived from those who choose to consent to the research opportunity from the new NHS GMS.

NHS England will act as the major data source for the future research function of the Project. In addition, NHS England will work in partnership with Genomics England to establish the Genomic Medicine Service infrastructure that will hold and process the data and results.

Other partners include:

- Public Health England
- Health Education England
- NHS Trusts
- Northern Ireland Department of Health
- HSCNI organisations
- Cardiff & Vale University Health Board (UHB)
- Welsh UHBS
- Welsh Government and Cardiff University (CU)
- Wellcome Trust
- The Wellcome Trust Sanger Institute
- Illumina

Alongside this there will be international partnerships with other nations and health providers e.g. the French genomic initiative Médecine Génomique 2025 and the British Columbia genomic initiative Genome British Columbia.

1.4 NHS Genomics Medicine Centres (GMCs) - 2015 to 2018
To identify and enrol participants and manage return of their results, NHS England sponsored and established NHS Genomic Medicine Centres (NHS GMCs). These regionally distributed centres harnessed the capability and capacity of the NHS across England between 2015 and 2018. It is likely their role will continue in some form to be defined by NHS England between 2018 and 2021.

The ambition to deliver the Project’s aims beyond England led to an extension within the devolved nations of Scotland, Northern Ireland and Wales.

To facilitate recruitment of patients in Northern Ireland, the DoH NI, in partnership with the Medical Research Council (MRC), commissioned the Belfast Health and Social Care Trust (BHSCT) to act as the delivery entity for a Northern Ireland Genomic Medicine Centre (NIGMC).

A joint agreement between the Welsh Government, Cardiff & Vale UHB, and Cardiff University allowed Welsh access to the Project. Delivery is governed by Cardiff & Vale UHB, which hosts the All Wales Medical Genetics Services (AWMGS). Cardiff University, who has secured MRC funding, is supporting Cardiff & Vale University Health Board.
The Scottish government, in partnership with the MRC, has ensured the inclusion of Scottish patients via a separate research protocol.

1.5 The NHS Genomic Medicine Service (NHS GMS) - 2018 onwards

The NHS has a history of providing genetic and genomic services in a clinical setting. This includes regional genetic laboratories, clinical genetic and cancer services and cancer molecular testing.

Development of the NHS GMS builds on this history, supported by the evidence generated by the 100,000 Genomes Project but extends to other genomic and multi-omic testing.

The future NHS GMS will be led and commissioned by NHS England and will consist of:

- NHS Genomic Medicine Centres (initially established by NHS England as part of the existing 100,000 Genomes Project infrastructure)
- NHS Genomic Laboratory Hubs that will work as part of a National Genomic testing service. The provisions in this service will be determined by a national genomic test directory that outlines the testing strategies and technology to be employed for rare disease, cancer and other defined conditions/applications.
- Clinical Genetic Services
- Cancer services using genomic analysis to guide treatment

In addition to the de-identified data held within the research infrastructure created for the 100,000 Genomes Project, a new clinical source of NHS GMS-commissioned WGS and all other genomic data will be added for those who consent to research. Appropriate governance will determine where data from the clinical service will be made available for research, dependent on patient choice for use of their data and samples.

The NHS GMS will be considered as the primary source of samples, clinical and research data. Other clinical services and research cohorts however, will comprise additional data sources to be used as part of the evolving data infrastructure made available for research by the Project. It is expected that this approach will potentially benefit all participants by allowing greater leverage for genomic data to improve diagnostics.

Participants will continue to receive the same research offer outlined in the Project, including opportunities for feedback to patients via the NHS, recall for research, international data access via the Genomics England Data Centre and opportunities for industry to develop new diagnostics, analytics or therapies as previously approved by the Research Ethics Committee. Some of these offers however, will be provided by the new clinical NHS GMS instead. Where a data source (cohort) is not sourced via the NHS GMS (or equivalent service), the full research offer outlined in historical versions of this protocol will continue to be provided by the Project.

The NHS GMS is a route for the provision of data and samples into the Project and similar arrangements will be open to devolved nations and appropriate cohorts.
1.6 Genomic testing including whole genome sequencing (WGS)
Next generation sequencing using massively parallel sequencing has advanced understanding of the
genetic architecture of disease.

Genomics England in partnership with the Wellcome Trust, the Wellcome Trust Sanger Institute and Illumina, have created the NHS Genomic Medicine Sequencing Centre in Hinxton. WGS is primarily undertaken at this site. Use of WGS in the 100,000 Genomes Project offers the opportunity to progress its application including:

• Detection of variants outside exons and a better representation of those inside exons.
• Improved detection of variants on intron/exon boundaries.
• Detection of an enhanced repertoire of variation including insertions and deletions (indels), copy number variants, and structural changes across the genome.
• Identification of variation that may encode other diseases.

Genomics England will continue to explore other providers of WGS, and new technologies, to ensure that the most leading-edge technology can be considered. Where a new technology shows promise of patient benefit, it may be introduced to the Project with non-NHS funding to help build a case for clinical commissioning. A similar approach will also be taken around methods that have the potential to improve sample handling, making the implementation of WGS pathways more feasible in healthcare.

In the NHS GMS, Genomics England will procure under a partnership with NHS England the NHS WGS requirement as outlined in the National Genomic Test Directory. The NHS will undertake all other genomic and multi-omic testing within the new Genomic Laboratory Hubs (GLHs). To allow us to undertake research, all tests and clinical data will be concentrated in a single NHS dataset as part of routine care (not part of this protocol). Each patient will be offered the opportunity to consent to take part in research. To fully realise the potential of data from the NHS GMS, the Project will concentrate results from all genomic testing - from a single targeted test to a WGS- to future commissioned omics and other technologies in the research dataset.

1.7 Key differences from previous Protocol versions

• The NHS GMS will become the main source of samples and data for the Project and all participants undergoing genomic or multi-omic testing in the NHS will be offered the opportunity for research (not just those undergoing WGS).
• The Infectious Disease Pathogen programme will continue to be implemented by the Public Health England.
• A single broad consent will be implemented for NHS diagnostic and research samples and data obtained via a clinical service route.
• The offer to patients taking part in the Project has not changed. However, in the majority of cases, the delivery of the participant benefits will be via a clinical service route, previously only provided by the research route. Governance for the clinical route is outside of this protocol.
Participants are to be recruited from within and outside of the NHS GMS. The NHS will be responsible for approving rare diseases, cancers and other diseases for the commissioned NHS GMS. The approval of research cohorts across rare diseases, cancer or other disorders and purposes e.g. population cohorts, will remain under the Genomics England Scientific Advisory Committee and Board.

The Project will continue to operate the research data centre as a “reading library” where web-based secure access is provided to researchers. However, we will make provision for participant consent to allow, where essential, the external sharing of de-identified data for maximum clinical benefit.

Important operational facts, including those relating to: Informatics and Information Governance; The Public Health England infectious disease genomics programme (runs independently of the Project).

New consent materials have been produced to record the patient’s choice in using their data and samples for research when undergoing a clinical genomic test. A proposed electronic consent form is available for review. Paper documents will continue to be provided to ensure equity of access.

1.8 NHS GMS-related impacts to potential participants

Potential participants of the research component of the NHS GMS are NHS patients who are undergoing genomic testing based on clinical indications as part of standard care, and as outlined in the National Genomic Test Directory that will be refreshed annually.

For patients within the NHS GMS, the choice for allowing routinely collected data and samples to be used in research will be offered alongside clinical consent for the test.

Consent will be obtained by the patient’s clinical team.

If extra samples and data are required for additional studies, further approvals will be sought from the appropriate governance forums (including NHS REC).

Other participants of the research component of the NHS GMS will be from existing cohorts. More details about the governance of these cohorts is provided in Section 3.3.

Results from the research environment will not be received by the participant directly, but via the NHS GMS (as in the current Project).
2 The structure of the Programme
2 The structure of the Programme

2.1 Beyond 100,000 Genomes (2018 onwards)

The Project consists of two main areas of focus based on the genomic or multi-omic testing strategy implemented via the NHS GMS. In addition, to ensure patient opportunities are maximised other disorders or population cohorts may be included (subject to consent):

i. Rare diseases and other diseases subject to germline genomic testing
ii. Cancers subject to somatic genomic testing (and accompanying germline testing where indicated)

This may develop over time as new genomic and multi-omic testing strategies are commissioned within the NHS GMS.

Within both programme areas, there are some common aspects:

- Main data and sample source will usually be the NHS GMS
- There will be potential for diagnostic benefit or tailored choice of therapy
- Opportunity to take part in further research
- Inclusion within the research infrastructure based on patient choice and consent
- Co-ordination of the clinical service through a single informatics and data service
- Adherence to the Project governance
- Inclusion of research cohorts sourced outside the NHS GMS, where appropriate
- Linkage to longitudinal data sources
- Collaboration of researchers to drive up clinical utility
- The requirement for clinical data to allow the interpretation of genomic data
- Cross-referencing of the genomic dataset to health datasets to provide improved individual patient diagnosis

As provision of data is based on real-world availability from a clinical service, the following is indicative of the approach to be taken but may be restricted by constraints on the availability of data and samples.

2.1.1 The Rare Disease Programme

The goals of the Rare Disease Programme are:

- To increase discovery of pathogenic variants for rare disease.
- To add value with additional biological insights that build confidence in putative pathogenic variants.
- To enhance the clinical interpretation of WGS in rare disease.
- To develop a programme of functional multi-omics pathways, specifically transcriptomics, epigenetics, micro RNAs and biomarkers.
- To return findings to the NHS for feedback to patients.
- To create a unique dataset for rare diseases that may enable therapeutic innovation.

Background to rare diseases
There are between 6,000 and 8,000 known rare diseases worldwide. Each disease or syndrome may affect less than 0.1 percent of the UK’s population, but cumulatively they affect the lives of 3 million people and are associated with substantial morbidity and mortality. Only 50 percent of the known rare diseases have an existing molecular diagnosis. Of these, 85 percent are associated with a single gene defect, although there may be modifiers elsewhere in the genome that have implications for treatment and outcomes. Recent research has shown that WGS can augment gene discovery by between 25 to 40 percent across a range of rare disease phenotypes (based on the Whole Genome Sequencing 500 study and the 100,000 Genomes Project early findings). Gene discovery in the Project will create significant opportunities for scientific innovation through routine service, our focus on residual unmet need, and our emphasis upon national and international collaborations.ii,iii,iv,v,vi,vii

**National and international collaborations in rare diseases**

Genomics England will work in collaboration with all important rare disease initiatives. In particular, we will actively support the implementation of the UK Rare Disease Strategy. Some key partners include the Deciphering Developmental Disorders (DDD) programme, the NIHR Translational Research Collaboration in Rare Disease (TRC-RD), the Whole Genome Sequencing 500 programme and the NIHR Bioresource in Rare Diseases (BR-RD).

Building on work already undertaken by the Project, this will facilitate the generation of a national data resource of all genomic data, with a focus on whole genome sequence but including all genomic testing. The national data resource will consist of families with rare diseases, based on family structures appropriate to the provision of the clinical service. More information on family structure guidance is available at www.genomicsengland.co.uk. This dataset will be enriched by other studies, including but not limited to, BR-RD, TRC-RD, and DDD through the Genomics England Clinical Interpretation Partnership (GeCIP). This will harness the strength of current UK rare disease programmes and will advance current understanding of rare disease mechanisms. It may also impact on common diseases that share similar phenotypes. It will also offer opportunities for biomarker, clinical, and interventional studies through industrial partnerships. This initiative is particularly timely as Public Health England have initiated a national registry for rare diseases and we are partnering with them to ensure the optimal outcome for patients.

The Project is expected to enable genomically-driven reclassification of rare diseases leading to opportunities to recall patients for deeper phenotyping through TRC-RD. These data will pave the way for functional characterisation of findings thereby adding further value to datasets, improving diagnostic utility and possibly identifying new targets and therapies.

**The NHS England Genomic Test Directory for rare disease areas**

Patients having any genomic test within the NHS will be offered the opportunity to participate in the next phase of the 100,000 Genomes Project.

The NHS England Genomic Test Directory will be maintained by the Genomics Unit at NHS England with expert advice from their advisory working group(s) and clinical panel. Where non-WGS testing provided under the Genomic Test Directory has not yielded a diagnosis, there is the potential to
offer whole genome sequencing within this infrastructure, should alternative sources of payment exist.

**Patient engagement and phenotyping strategy for rare diseases**

Genomics England will work in partnership with NHS England, Wales and DoH NI (operating through its arm’s length body BHSCT) to engage, recruit, and characterise patients with specific rare diseases, with residual unmet diagnostic need. A managed network of NHS Genomic Medicine Centres (GMCs) (including NIGMC and the Wales GMC) has been established across England, Wales and Northern Ireland. It is expected that the English NHS GMCs will work within a performance managed network and within the evolving commissioning structure in the new Genomic Medicine Service. Separate arrangements and agreements exist for the establishment, operation and governance of the NIGMC and Wales GMC, based on similar contractual arrangements as English NHS GMCs. It is hoped Scotland will also participate.

NHS healthcare teams will be responsible for offering research participation to patients and family members following agreed Standard Operating Procedures and appropriate consent. They will also be responsible for the provision and recording of core clinical phenotypic and demographic data on patients and relevant family members.

Consent will follow standard requirements for clinical genomic testing, including data requirements. If identified, this data will be collected through a national genomic informatics service as part of a commissioned service. It is intended that this will also include the capacity to digitally record participants’ consent decisions. However, paper copies of consent materials will also exist to ensure equity of access.

**Clinical phenotyping in rare diseases**

For testing carried out under the Genomic Test Directory, clinical data collected will be appropriate to the requested genomic test.

For WGS, within each disease area, a core set of characteristics and data points has been defined in consultation with clinicians and researchers with relevant expertise. In most cases, this will include a number of statements made using a phenotyping ontology. Although the Human Phenotype Ontology (HPO) is currently being used, other ontologies may also be employed. Data will continue to be recorded using controlled, clinical terminologies wherever possible for consistency.

The NHS number / Health and Care (H&C) number (for Northern Ireland participants) (and other core demographic data) will be recorded for each participant, including the biological relatives recruited as part of a trio or duo for patients with rare disease. A family tree and history of diseases will be recorded for parents and all offspring. The NHS/H&C number will be used to identify and link to relevant health and social care records, providing additional context for the core phenotypic data.

A secure, web-based, information system will be provided for the collection of this data, removing the need for any additional, bespoke development within participating NHS organisations. An electronic facility will be provided for transmission of the same data from existing information
systems. Where organisations have developed their own capacity for capturing and managing the same data, to the same standards, there will be no requirement for additional data entry.

Each rare disease may have a different set of phenotypic characteristics ranging across clinical features, laboratory tests and imaging. We will use published literature, ontologies and expert advice to help with development of systems to capture these characteristics from existing health records in increasing numbers of clinical contexts. In cancer, we collected standardised clinical datasets that may include tumour specific features or staging related to tumour type which will typically be provided by routine data feeds to national cancer registries held by PHE.

**Genomic testing strategy and quality assurance (excluding whole genome sequencing).**

For genomic testing performed by the GLHS, standards will be set across the NHS by NHS England and informed by Genomics England.

**Whole genome sequencing strategy and quality assurance for rare diseases**

Our initial approach for the main programme was adapted from experience gained in the WGS500 study as well as advice from UK and international experts and information from technology providers. For rare diseases, Genomics England has sequenced whole genomes in all members of the family trio (proband, mother, and father) for most disorders, where available, but has adapted its processes to sequence other family structures as information emerged from the pilot programmes and other efforts worldwide. Family structures in the future will be determined by the route of sample collection, but trios will continue to be sequenced wherever possible.

DNA sequencing for the main programme has been contracted through Illumina. This was informed by the results of an earlier sequence evaluation exercise. Although there is currently only one sequence provider in the programme, we expect that multiple instruments and chemistries will be applied throughout the lifetime of the Project as the technology matures. Sequencing standards will therefore be maintained and enhanced as appropriate through the requirement to meet platform independent metrics (as detailed in the Sample Handling Guidance, latest version to be found at [https://www.genomicsengland.co.uk/information-for-gmc-staff/sample-handling-guidance/](https://www.genomicsengland.co.uk/information-for-gmc-staff/sample-handling-guidance/)).

The data generated will be transferred encrypted via a dedicated 10G link to the Genomics England Data Centre. For any genomes arriving externally the method will be reviewed and agreed.

Genomic testing supplied under the NHS GMS will be provided as agreed with NHS England.

Genomics England will capture quality metrics for WGS per run and routinely check for the presence of batch effects at the run, flow cell, and lane level (as applicable to the technology) to ensure that sequence quality is maintained and to aid its improvement over time.

**Alignment and identification of sequence variation**

It is expected that as sequencing technologies evolve, sequencing will continue to align with the clinical service. As part of the sequencing contract, providers will supply sequence data aligned to the reference genome (currently GRCh38) and in a standard file format (currently BAM). They will also identify sequence variants and report them in a standard file format (currently VCF). It is
expected that the mapping and calling pipelines will report single nucleotide polymorphisms (SNPs), short indels (<50bp), copy number variants (CNVs) and structural variants (SVs). It is also expected that our pipelines will incorporate processes to jointly call across family data. This will ensure that missing sequence data is distinguished from that identical to the reference and that putative haplotypes are generated to the extent possible, depending on the underlying sequence fragment lengths. Pipelines should also identify regions of the genome with inadequate coverage for reliable variant calling. Genomics England will define clear Standard Operating Procedures in partnership with NHS England for the WGS NHS-commissioned service and will revise and inform the NHS of any changes as these evolve over the life of the Project and its legacy.

Genomics England will routinely assess the quality of the mapping and variant calling provided and compare this against alternative algorithms to ensure the data has been processed with the best available pipelines.

Interpretation of sequence variation

The interpretation of sequence variation will move to a clinical governance framework and is expected to work in the following manner. To provide timely analysis to support interpretation against specified and clinically agreed turnaround times, we will have a core sequence interpretation service. This may consist of internally-run filtering processes (e.g. a tiering algorithm) and inputs from external interpretation providers through competitive tendering. These are known as decision support providers (DSPs). These annotations will also be available to researchers within the Genomics England Data Centre.

In the NHS GMS as part of clinical service, the output from this pipeline will be presented to clinical scientists in the NHS GLHs in the form of a web-based decision support tool; enabling the final manual interpretation and reporting step that will be carried out within the network of NHS GLHs. WGS entering the Genomics England Data Centre from other sources may also be run through this pipeline and returned by a similar route, where appropriate.

Pipelines will be expected to evaluate all modes of inheritance. They will also identify long regions of homozygosity (LROHs), particularly where consanguinity is suspected, and in such regions, identify potentially pathogenic homozygous variants. In terms of identifying variants most likely to have functional consequences, it is anticipated that pipelines will evaluate variants using various prediction tools (e.g. Ensembl Variant Effect Predictor, Sift, and Polyphen), as well as checking against databases of known pathogenic variants (e.g. ClinVar). Variant annotation will be updated regularly, and snapshots of previous annotation versions will be stored and versioned.

2.1.2 The Cancer Programme

Goals of the cancer programme

The goals of the cancer whole genome sequencing programme are to:

- Use WGS to identify novel driver mutations for cancer and to understand its evolutionary genetic architecture through primary and secondary malignant disease (by multiple biopsy and WGS).
- Partner stratified healthcare programmes and outcome studies with patients from the NHS in England, to enable understanding of WGS benefits in defining predictors of therapeutic response to cancer therapies.
- To use multi-omic approaches including transcriptomics, proteomics and epigenetics to offer additional biological insights into cancer.
- To utilise WGS to identify new pathways for cancer therapies and improved diagnostic characterisation.

### The inclusion of specific cancers

Cancer is fundamentally a genetic disorder where mutations (including copy number aberrations, indels (insertion/deletion variants), complex rearrangements, and non-synonymous substitutions) lead to uncontrolled cellular proliferation. The clinical impact of sequencing technologies has enabled precise definitions of disease, uncovered mechanistic insights into pathogenesis, and identified therapeutic targets based on genetic variation or aberration. Additionally, sequencing approaches have catalogued the complex evolutionary changes that occur in an individual’s cancer under the effects of treatment and time. This has demonstrated that there are both expanded clonal populations and the existence of low frequency sub-clones, each with specific genomic architecture. viii,i,ix,x,xi,xii,xiii

Meta-analysis across cancer types has confirmed the importance of at least 200 key genes in driving cancer. However, focusing only on these genes with targeted re-sequencing will be insufficient to significantly impact on the majority of individuals with cancer. Overall response rates to targeted agents with ‘actionable’ mutations have been relatively modest. The differences in response between patients with mutations in the same gene suggest complex interactions between identified activated pathways and the genomic environment in which they occur. Moreover, power calculations and saturation analysis suggest that many more cancer gene regions remain to be found (see Section 3.4 sample size requirements). In many cancers, the ‘actionable’ gene may not be the dominant driver. Furthermore, recurrent oncogenic mutations are rare and some of the putative driver mutations are caused by copy number aberrations or complex rearrangements that cannot be globally ascertained with gene panels, thus WGS or orthogonal tests are required.

The Project will continue to learn from and collaborate with the Cancer Genome Atlas (TCGA) project and the broader International Cancer Genome Consortium (ICGC), who are producing an inventory of genomic, transcriptomic and epigenomic changes in a wide range of different tumour types.

A list of NHS England-approved cancer genomic tests will be provided in the National Genomic Test Directory. Where there is external funding for the investigation of cancers beyond the NHS GMS (e.g. via the Cancer Fund), the principles for inclusion are described below.

### The NHS England Genomic Test Directory for the cancer programme

NHS England evaluated each cancer type for inclusion in the NHS commissioned service. Every proposed disease was assessed by experts in specific transition groups, who then made recommendations. As above, the opportunity exists to add new cancers either to the NHS service or to the research programme following expert advice.
A small number of cancer subtypes are eligible for WGS within the first version of the National Genomic Test Directory. These indications were selected because they fulfilled one of the following criteria:

- For any individual sample, a large range of separate genomic tests are already performed as standard of care that could (pending appropriate validation) be replaced by WGS (e.g. acute leukaemia).
- They represent a broad group of relatively rare cancers with disparate histologies, where although for any individual tumour only a small number of genomic tests may be required- collectively as a sample group a large range of different genomic tests (infrequently performed) is required to be available which could (pending appropriate validation) be replaced by WGS (e.g. paediatric tumours).

Work is ongoing to build a case for commissioning WGS in other cancer types and for now, other forms of genomic tests are specified through the Test Directory.

Comparable to rare diseases, consent will also follow standard requirements for clinical genomic testing, including data requirements. If identified, this data will be collected through a national genomic informatics service as part of an NHS England-commissioned service. It is intended that this will also include the capacity to digitally record participants’ consent decisions. However, paper copies of consent materials will also exist to ensure equity of access.

**Inclusion criteria for cancers:**

- A cancer from the NHS England Genomics Test Directory approved list or a Genomics England approved nomination by the NHS, academics, or industry.
- Capability of the NHS in England/HSCNI to recruit, supply samples, and upload data from patients.
- Access to appropriate high-quality DNA from both tumour and germline samples, derived in the overwhelming majority of cases from fresh tissue preparation for WGS, according to the Sample Handling Guidance provided by Genomics England and/or NHS England.
- Existence of consent and upload of the phenotypic data required for diagnostic testing.
- Timelines for recruitment that are in line with Genomics England Standard Operating Procedures.
- The existence of sufficient resources to perform WGS within the Project, or an independent source of funds to complete sequencing in all planned recruits e.g. from a GeCIP funder.

**Exclusion criteria for cancers:**

- The absence of consent, unwillingness to give consent or participate in all aspects of the Project (excludes opt-out of feedback).
- Inadequate phenotyping, or failure to upload phenotypes to the Genomics England Data Centre.
- No access to matched tumour and normal DNA samples.
- Patients not under the care of the NHS in England or HSCNI.*
• DNA of insufficient quality for WGS, or failure to adhere to the Sample Handling Guidance or other SOPs provided by Genomics England or endorsed/coproduced by Genomics England and issued as part of a clinical service (e.g. that for the NHS GMS by NHS England).

Phenotyping of patients participating in the cancer programme

For each disease area, a set of phenotypic characteristics or data points will be defined in consultation with clinicians and researchers with relevant expertise. This core phenotypic data set will be aligned with the needs for clinical reporting. Additional phenotypic data sets will be aligned data sets for cancer such as, the Cancer Outcomes and Services Dataset, the Systemic Anti-Cancer Therapy Dataset, and the Radiotherapy Data Set. These will also be aligned with the clinical audit data sets collected for specific cancers: colorectal, lung and prostate, to avoid duplication of effort. Data will be recorded using controlled clinical terminologies, and structured ontologies wherever possible.

The NHS/H&C number (and other core, demographic data) will be recorded for each participant. This information will be used to identify and link relevant health and social care records, providing additional context for the core phenotypic data. It will be used also to identify and link registry and audit data, where this is available.

The structures being built for the National Genomic Informatics Service will be the system for both collecting and providing the relevant cancer data for the NHS GMS. This will also be used as a mechanism for acquiring data for cancers included but outside of the NHS GMS.

There is an expectation that the phenotypic data will be provided within clinically-appropriate timelines in order to enable the return of results. Samples will not be sent for sequencing until genomic and somatic DNA of sufficient quality and a minimum data set, have been supplied. Whole genome sequencing will not be undertaken until the dataset, and QA processes are submitted with sample.

DNA quality assurance from cancer samples

National standards for DNA quality for all genomic tests can be found in the sampling handling guidance (www.genomicsengland.co.uk). This may change as the NHS GMS develops. As part of the NHS GMS only fresh frozen samples (FF) will be eligible for WGS except in exceptional circumstances or where there are developments in the technology that allow other approaches.

Additional samples for multi-omic functional studies

We will seek additional funding for appropriate RNA, plasma, and serum allowing the acquisition of expression, methylation, epigenetic data and serum or plasma biomarkers pertaining to the same samples used for WGS. These samples will be collected and stored at the central biorepository or NHS biorepositories and will add the value of functional analysis to the WGS. We have a significant opportunity to apply our expertise in detecting temporal changes in cancer genomes (in cell-free tumour DNA in plasma) to develop non-invasive ‘liquid biopsy’ based on WGS or broad targeted panels. This could provide a cost-effective means of disease monitoring, to enable innovation in trial design and encourage industrial investment in UK clinical research.
Whole genome sequencing strategy and quality assurance for cancer

Our current approach is being adapted with advice from UK and international experts and information from technology providers. Moving forward, Genomics England will continue to sequence germline samples using the same criteria as for rare diseases samples (see above).

For tumour DNA, we will continue to sequence at least 75X coverage. However, in some cancers, greater depth of coverage may be required and we will continue to modify this as necessary.

WGS will continue to be performed using the same technology and QC approaches outlined for the rare diseases programme. In addition, we will continue to monitor the frequency of single nucleotide variations (SNVs) potentially caused by DNA alterations created during the FFPE process, (such as G to A, or A to G transitions) due to PCR amplification.

Identification of sequence variation

For the cancer programme, sequence providers will continue to carry out initial steps in read mapping and variant calling to deliver BAM (Binary Alignment Nap) and variant call files (VCF files), for both germline and tumour samples. In addition to the requirements outlined for rare diseases, we expect pipelines to jointly call across tumour-germline DNA pairs, to identify somatic variants and report the purity of the tumour sample. This is specific to cancer.

Annotation of sequence variation

The interpretation process will continue to distinguish between somatic variants, those mutations acquired by the cancer, and cancer susceptibility germline mutations that might have increased the overall lifetime risk of developing that cancer. For germline, annotation will exclude known benign common variants using internal allele frequencies and datasets such as 1000 Genomes, Exome Sequencing Project, and UK10K. The annotation of somatic variants will continue to highlight those found in known cancer genes and identify them as being likely to result in loss of function. To determine the likely importance of variants, it is expected that reference will be made to general cancer databases such as COSMIC, as well as gene specific databases, such as the IARC TP53 mutation database and other resources where appropriate.

A major component in cancer annotation is analysing the consequence of larger scale genomic changes, such as structural variants, copy number aberrations, loss of heterozygosity and other chromosomal mutational events.

As some genomic changes are not unique to the tumour sample, paired approach to the analysis of the two samples will continue to be important to ensure the origin of the variant is clear. Regarding the annotation of individual sequence variants, the consequence of copy number and structural variants will be assessed for their impact on genes implicated in cancer.

The variability in tumour sample purity, both with respect to contamination with normal tissue and the likely presence of multiple tumour sub-clones, is a particular challenge to interpretation pipelines. It is crucially important that in addition to paired analysis, the tumour is also analysed separately. This will ensure that key somatic lesions are not filtered out by the variant calling algorithm, due to tumour contamination in the germline sample.
The results of interpretation are fed back to patients via an NHS genomic multidisciplinary meeting as described in section 5.

2.2 The Genomics England Infectious Disease partnership with Public Health England

While the Infectious Disease Pathogen Programme formed an important part of the 100,000 Genome Project, it will continue to be implemented by Public Health England. Currently, the data from this programme will not be included in the data centre.

2.3 Sample size considerations for research in rare disease and cancer

**Rare Disease Sample sizes**

The NHS GMS will be obliged to test patients identified through clinical care to obtain a diagnosis for them, as part of a duty of care. Therefore access to testing cannot be governed by power calculations. For research - sample sizes in rare disease are affected by the available number of families, the mode of inheritance, penetrance of the genetic variation and the depth of phenotyping. Different types of variation may be detected more readily by specific tests. Below we depict power simulations for research that allow researchers to gauge under different scenarios the likelihood of detecting a pathogenic mutation.
**Figure 1.** Different rare disease experimental designs are marked by arrows below. The number of detected mutations in cases required to pass genome-wide significance ($p < 2 \times 10^{-6}$) is shown by the italic numbers on the power curves (only numbers five or smaller are shown).
The Genomics England Data Centre will contain all of the genome data from the 100,000 Genomes Project, together with other WGS cohorts from external collaborators, and will be added to year on year by samples obtained via the NHS GMS; this will result in one of the largest collections of genomic data in the world. For individual research questions, data will be available to allow cohort size to be assessed and power calculations to be applied in planning methods to address research hypotheses. Where the data centre contains insufficient samples to address a particular question, routes to address this will be discussed with the research team.

Cancer power simulations

Again, the NHS GMS will be obliged to test patients identified through clinical care to obtain a diagnosis for them, as part of a duty of care. Therefore access to testing cannot be governed by power calculations. To assess the power for research purposes, in cancer studies we have considered the sample size needed to detect a gene containing pathogenic coding variation, we characterise a particular study by the rate of neutral variation in healthy individuals (the x-axis below) and the rate of pathogenic variation (the coloured lines below; i.e. the fraction of cases caused by a mutation in the relevant disorder). The following calculations and plots generalise the results of Lawrence et al 2014.

![Figure 3](image-url)

**Figure 3.** Sample sizes required for 90 percent power to detect a disease associated gene under different scenarios at a genome-wide significance level of \( P = 2 \times 10^{-6} \). The x-axis shows the probability that the gene contains a relevant missense mutation/variant in a healthy individual (a function of gene size, mutation rate, and genetic model). The coloured lines show the power required for different frequencies of pathogenic mutations in that gene. We looked at two example genes for each tumour, the most commonly mutated.

© Genomics England Limited 2018
In the above figure, the solid arrow depicts the range of sample sizes needed to detect the most commonly mutated gene (e.g. TP53 in ovarian and lung cancer, and APC in colorectal cancer). Studies with sample sizes below these solid arrows will find no significant genes at all. The dashed arrow shows the most infrequently mutated known gene. To start finding many new genes in any of these tumour types, you need to have a sample size above this dashed arrow. The arrows are sloped to show the increase in sample size you would need, to find more mutagenic genes at this frequency. Although it is likely new genes will be detected as sample sizes increase above the left-hand side of the dashed arrow, to be well powered across all genes, you will need sample sizes to exceed those indicated on the right-hand side of the dashed arrow.

In cancers where there is only one known gene (rhabdomyosarcoma, carcinoid, and neuroblastoma), and they are expected to be relatively oligogenic, there is only one arrow. This analysis shows us that lung cancers will be the hardest to solve (dashed arrow 19 and 20 on Figure 3).

In lung cancer, significant genes containing driver somatic mutations such as TP53 will be detectable in <30 samples. A study that is powered to detect new lung cancer genes would need to have a very large sample size to get over the high mutation rate, e.g. 5,000 cases at minimum, ranging up to >20,000 to pick up larger, or more mutagenic causal genes (the right-hand side of the dashed arrows 19 and 20 in Figure 3).

The genetic architecture of some cancers such as prostate or medulloblastoma, may require sample sizes of <1,000 to discover many novel lower frequency (1-2 percent) somatic mutations.

Breast cancer has a reasonably low mutation rate, and lots of common driver genes (PIK3CA, PTEN, and P53 are each mutated in about 1/3 of cases). Therefore studies ranging between 30-50 samples will find plenty of genes. However, as this is a very heavily studied cancer, many of the rarer genes have already been found. To significantly add to this set and make new discoveries, a study design will need to have 3,000 to 10,000 samples to be well powered.

2.3.1 Declaring significance
Genome-wide significance, correcting for the number of genes in the human genome, is typically defined as p<2x10^-6. The number of detected mutations in cases required to pass genome-wide significance is shown by the italic numbers on the power curves in Figure 1 (only numbers five or smaller are shown).

2.3.2 Variation in gene size and mutation rate
The median human gene has 1,293 coding bases and a mutation rate of 1.2x10^-8 bp/generation. The 90th percentile of gene size is 3218 base pairs, and the 90th percentile of mutation rate is 3.9X, the median rate. In Figure 1, the arrows for rare disease show the range of background variation, from the median gene on the left, and a large mutable gene on the right. For cancer in Figure 3, this is shown by solid or dashed lines.

2.3.3 Genetic architecture, and discovering genes vs solving diseases
We model disease heterogeneity as a geometric distribution, i.e. the fraction of cases caused by mutations in the most commonly mutated gene is x, the fraction explained by the next most
commonly mutated gene is $x(1-x)$, and the fraction caused by the $n$th most common gene is $x(1-x)^{n-1}$. Although this is a crude approximation, it is probably conservative.
3 Opportunities to extend beyond the primary phenotypes
3 Opportunities to extend beyond the primary phenotypes

3.1 Opportunities to extend beyond rare diseases, cancer and infection

3.1.1 Lifelong electronic health record linkage
Genomics England’s partnership with the NHS is particularly important to deliver high-quality initial phenotyping data; a flow of electronic health data from primary care, hospital, outcomes, registries and social care records; and an opportunity to work with clinicians and patients to acquire further information on the primary conditions, associated comorbidities and outcome. This information will further enhance the research dataset.\textsuperscript{xv}

The evaluation of WGS data in the context of rich and extended phenotypes derived from electronic health records, such as blood pressure, cholesterol, glucose, and pharmacogenomics, adds significant value. The richness of the Project dataset will allow us to move beyond the primary phenotype of the rare disease, cancer or infectious disease that led to the patient’s initial WGS in the context of other continuous traits, diseases and response to therapy including harm. To do this, we will partner with Health Data Research UK as appropriate.

3.1.2 NHS and public health registry data linkage
A key benefit of patient involvement in research concerns the linking of data to wider datasets and the potential direct clinical benefits that may stem from this. As these benefits are determined, we hope to incorporate them in the clinical diagnostic process. We will continue to build on this work throughout the lifetime of the Project.

We provide data to NHS Digital and Public Health England and will do so to any appropriate organisation holding relevant data on our participants. This enables them to extract data from their systems, which they then pass back to us to form the richest possible datasets on which we carry out our research.

NHS Digital, Public Health England and other NHS organisations are responsible for the national and local patient-level registries for several areas relevant to the Project, including cancer and rare diseases. The National Cancer Registration Service collects data on every patient diagnosed with a cancer-registerable condition across England. The data is collected from sources covering the whole pathway from referral, screening, to palliative care. It combines diagnostic, treatment and outcome data, including individual patient reported outcome measures. Data is normalised and quality-assured. There are systems to feedback the data, alongside comparative performance reports, to individual clinical teams and clinicians. This will provide a continual incentive for its improvement.

The National Congenital Anomaly and Rare Disease Registration Service (NCARDRS), part of the UK Rare Disease Strategy, was launched in 2015 and now covers the whole of England.

Similar benefits in terms of access to data are likely to accrue (as seen for the linkage to cancer data) as it continues to develop. As well as being a key source of phenotypic data linkage, this dataset will help inform the genetic makeup of the epidemiology of the diseases (by assessing how representative the sample is of all cancers/rare disease of that type).

There are a number of other health datasets, referred to in Section 9.
3.2 Opportunities beyond whole genome sequencing

We propose to continue to create a high quality biological sample resource from participants in support of future health research, where there is available funding for this. An essential element of this collection is to provide a resource that supports scale (power) and diversity (of sample types and analytic options) across different ‘omics’ platforms. The National Genomic Test Directory along with the sample handling guidance detail the tissue handling and sample requirements for each test. We intend to continue to collect the following samples in the NHS GMS and the NIGMC as appropriate:

- Serum and plasma for proteomics and metabolomics.
- Cell-free serum for circulating tumour DNA and to assess tumour recurrence.
- Germline RNA for transcriptomics.
- Lymphocyte DNA for epigenetics.
- Tumour for RNA expression profiles, tumour epigenetics and proteomics.

The NHS GMS, and the infrastructure used to support it, will continue to have the ability to collect samples of these types and others, where funding is available from research via Genomics England or any other funding route that has been agreed by Genomics England and NHS England.

We recognise other types of sample collection may be valuable for research but they will need a specific consent. Examples of these may include:

- Cancer cell lines for study or xenotransplantation cancer models (not funded at present).
- Skin biopsies for generation of inducible pluripotent stem cells will be possible under additional consent if funds are raised (not funded at present).
- Tissue specific RNA samples may be collected from individuals where a putative splice variant requires assessment.

The collection of these samples will ensure that biological samples obtained are suitable for assessing the genome, epigenome, proteome and metabolome in blood and tumour. The storage and processing of samples will account for the assays that are considered most likely to be used in the future. For example in WGS, transcriptomic, epigenetic, metabolomics and proteomic research. These samples will bring potential to look at a complete functional pathway - from DNA to the transcription pathway and genetic modifiers to metabolites, and the associated development of companion diagnostics and other technologies.

3.3 Opportunities for recruitment beyond the NHS GMS/clinical services

The primary source of data and samples for the Project will be the NHS GMS. However, in a number of cases there are cohorts of patients or population cohorts, who have had their samples and data taken for research or as part of clinical care. These are outside of the funding and structures of the NHS GMS. Individuals who are part of these cohorts, or whose data can be sourced via alternative clinical services to the NHS GMS, would benefit from being included within the Project and their inclusion may help to realise the clinical benefit for those participants who are recruited via the standard diagnostic service structures. Examples of these benefits include:
• A larger set of genome and phenotypic data that allows greater accuracy in, for example, identification of rare variants that will likely improve the diagnostic rate of all individuals who participate.

• Inclusion of trial cohorts of cancer patients where some of the trial data can provide valuable insights that will inform development of cancer genomic clinical reporting functionality, future treatment and diagnosis.

Where patient samples already exist that meet the technical requirements for sequencing and appropriate sample metadata, clinical data and other data is available within existing cohorts, these could be processed via the NHS GMS or Genomics England infrastructure. This is in line with the clinical transformation aspects of the Project, and as would be expected in standard clinical care.

The overriding principle behind this is that where possible it would be inappropriate in a clinical setting to put individuals through ‘additional’ procedures, such as the collection of blood.

While recruitment via NHS GMS will be the main source of data and samples, it may not always be feasible for clinical, operational, technical, contractual or governance reasons for patients to be recruited for research via this route. For example, where individuals have been recruited through an existing clinical structure it may be in the participant’s interest that results are returned via the same structure e.g. this could apply to devolved nations.

To adhere to the above principle and to ensure equity of access to the programme including equity of direct patient benefit for taking part in research activities, the Project has the following approach for participants recruited outside NHS GMS structures.

• A standard operating procedure (SOP) for initial assessment of requirements and systems that need to be put in place for mobilising research cohorts appropriately.

• A governance approach led by Genomics England that allows a legally binding agreement to be put in place with the responsible individual/organisation for the cohort that sits outside the NHS GMS.

The specific responsibilities outlined in the legal agreement will be informed by the assessment of requirements and include, but are not necessarily limited to, responsibility for ensuring the following areas are enacted in a manner equivalent to those in place via NHS GMCs:

  a. recruitment and consenting
  b. provision of samples and requirements sample quality, including replacement samples if required or duty to inform participants if they become ineligible due to sample quality issues (note, in some cases it may be provision of existing genomic data where sequencing has been undertaken elsewhere)
  c. provision of relevant sample metadata, clinical data and other data
  d. analysis of genomes, including the Genomics England bioinformatics analysis pipeline and provision of relevant genomic testing knowledge base
  e. mechanism of return of results and relevant clinical support or referral for additional findings (where these have been requested).

• Standard resources requirements to project manage the operational aspects of mobilising the cohorts.
• Inclusion in Project governance and oversight structures of ongoing checks that obligations to participants are being met.

While it is envisaged that this mechanism would mainly apply to research cohorts meeting the criteria for inclusion within the rare disease or cancer programme areas, this route may also be particularly appropriate for including cohorts with a focus on complex diseases or those thought to be of polygenic origin into the programme. Research into these disorders is within the programme’s remit (e.g. via the linkage and analysis of secondary data sources with genomic data) but presentation of these phenotypes is not currently a direct reason for recruitment via NHS GMCs. There is a growing body of evidence being developed around, for example, polygenic risk scores that suggest genomic data is likely to be of importance to direct clinical care. The longer term transformative aims of the programme include providing the ongoing evidence base for consideration of adoption of these new approaches within the NHS GMS and beyond. In the rare disease programme, it is already recognised that for many participants the benefit in direct care regarding their pertinent disease may only occur after further research and gene discovery, similarly in the cancer programme the main clinical benefit may be for individuals with a recurrence of cancer. As such, expectations of immediate compared to future potential clinical benefit and the possibility that there may not be a direct benefit to the patient are covered in the consenting process. However, for cohorts with complex disorders we can be more certain that the potential direct clinical benefit regarding the individual’s pertinent disease is likely to be over a longer time period. In such circumstances the legal agreement outlined above would more explicitly cover responsibility for:

• Ensuring this is understood by participants
• Ensuring that appropriate provision is in place for realising the clinical benefits

Requirements around ensuring the realisation of other benefits to participants, e.g. for those who opt for return of additional findings, would be the same.

Similar considerations apply to cohorts where an existing molecular diagnosis is known but genomic data is identified as important in understanding the presentation and prognosis of the disease.

This approach makes it operationally feasible to include additional cohorts from trials and research studies, in a manner that helps us to achieve major aims of the programme i.e. patient benefit and research.
4 The Genomics England Clinical Interpretation Partnership (GeCIP)
4 The Genomics England Clinical Interpretation Partnership (GeCIP)

The overall aim of the Genomics England Clinical Interpretation Partnership (GeCIP) is to create a thriving, sustainable environment for researchers and clinical (NHS) disease experts, trainees, and an industrial engagement approach, including both direct and consortia engagements. This will stimulate and encourage new research endeavour and information exchange. This community will analyse and constantly refine the clinical and scientific interpretation of the Project dataset. The intention is to further improve understanding of findings and their implications for genomic medicine and the clinical setting. GeCIP was launched at the Wellcome Trust on 27 June 2014.

GeCIP will also provide an excellent basis for further research and development in genomic medicine in the UK by academics and industry. All GeCIP users will be required to contribute results and data to the Genomics England Data Centre to enhance the scientific knowledge base. All data is available to all GeCIP members who have access to the Research Environment, however, a nine-month moratorium on presentation and publication is applied from entry of data into the Research Environment to allow GeCIP domains to have priority access to samples that they were responsible for collecting.

The scientific aims of the GeCIP programme are as follows:

- Enhanced clinical interpretation focused on rare disease, including clinically or genomically-driven deeper phenotyping, novel approaches to interpretation and annotation, validation and functional characterisation of variants, identification of novel therapeutic targets, or repurposing of existing therapies. Rare disease will also be informed by other ‘omic’ investigations.
- Innovative clinical interpretation in cancer, including multi-omic datasets (e.g. transcriptomics, epigenetics, and proteomics), analysis of circulating tumour DNA, sequential biopsy to address the genetic architecture of cancer, validation and characterisation of variants, identification of novel therapeutic targets, or repurposing of existing therapies.
- Expand the programme to include other disease areas with additional funding, to address specific research questions and opportunities to develop stratified approaches. The Genomics England infrastructure will be designed to facilitate expansion and reuse, and individual GeCIP partnerships can be extended to programmes (with funding) outside of the Project and its legacy.
- To capitalise upon electronic health records research, we can build upon and add value to the clinical, laboratory and health records data, linked to variant call data, which is held securely within the proposed data and computing infrastructure.
- Algorithms, models, and tools for clinical genomics research, data quality assurance, and the annotation, interpretation and presentation of genomic, clinical, and laboratory data in combination, may be developed, evaluated, used, and shared within the proposed infrastructure.
All GeCIP partners will adopt the highest ethical standards in accordance with the terms of the Genomics England consent. This will be with the continued support and advice of the Genomics England Ethics Advisory Committee and the GeCIP Board, comprising representatives of the GeCIP community and funders of GeCIP activities (see section 5.7).

The activities of GeCIP will inform clinicians and multidisciplinary teams within the NHS GMS, by providing enhanced data interpretation, additional information on pathogenicity of variants, and functional characterisation. The process of NHS feedback of research findings will be managed by Genomics England and, for the NHS GMS, the Genomics Unit at NHS England. The details for this process are outlined in Section 5.

4.1 The route by which researchers add value to GeCIP

It is the ambition of Genomics England and the GeCIP funders, to see a really strong research and training programme alongside the evolving Project. This will create opportunities for GeCIP researchers and trainees, which will stimulate and support research programmes funded by GeCIP funding partners, through response mode and specific funding calls. The researchers leading these programmes will have access to appropriate patient groups from the NHS in the UK (see later for details related to the devolved nations). They have formed and now lead appropriate national and international consortia within cognate domains that provide NHS samples, clinical data, and analytical skillsets. This will maximise the value of the dataset and ensure that the clinical interpretation delivered by the Project and its legacy remains at the forefront of genomic medicine. This may be achieved in a variety of ways, including:

- Enhanced clinical interpretation focused on rare disease. Omic data will also inform this.
- Innovative clinical interpretation in cancer, including multi-omic datasets.
- Expanding the Project and its legacy to include other disease areas beyond cancer and rare diseases.
- A researcher or trainee can become a member of the GeCIP provided they work according to the Genomics England policies (including those funded specifically to work within the Project by a GeCIP funding partner).
- If a research proposal or training fellowship is planned, it is recommended that applicants contact the Chief Scientist’s team, so they can ensure compatibility with the mission and assist where necessary.
- Delivery of health records research using the linked, longitudinal dataset.
- Delivery of algorithms, models, and tools to facilitate interrogation and analysis of linked, longitudinal datasets.
- Work as part of the clinical validation groups to review data and interpret findings (see below).
- Commitment to provide results or findings to the Genomics England Knowledge Base, in addition to publication to the wider scientific and medical community.
4.2 The route for those who contribute patients and data from the NHS to add value to GeCIP

GeCIP will be the route for NHS and other organisations who recruit patients, contribute samples, and/or data to the research programme, or those funded on specific NHS training programmes related to Genomics England (NHS Trusts, NHE England, Public Health England, and Health Education England) to carry out research using the data. This offers the opportunity for those in contributing NHS organisations to participate in the analysis and interpretation of sequencing, to inform release of clinical reports back to the NHS.

Contribution from the NHS could include:

- NHS contributor who adds value to the GeCIP (e.g. samples, data, annotation, tools etc.).
- Delivery of updated clinical, phenotypic, and laboratory data on patients (through existing Genomics England tools and pathways).
- Working as part of the clinical validation groups to review data and interpret findings.
- Committing results/findings to Genomics England knowledge base.

4.3 Establishing and working within the Clinical Interpretation Partnership

The GeCIP has been organised into a series of disease-specific domains by an open call - in which UK researchers, trainees and clinicians self-organised and created proposed GeCIP domains. Key selection criteria were published in the GeCIP guidance document accompanying the call. Successful GeCIP proposals clearly articulate the value they will add to the clinical interpretation of the Genomics England dataset.

Researchers, NHS clinicians/healthcare professionals and trainees will work as part of disease-facing or cross-cutting domains (depending on their area of expertise), contributing patients, phenotypes, knowledge, expertise, and undertaking research to add value. This work will be continuous, as the dataset is updated with patient outcomes and detailed clinical, phenotypic and laboratory data, which is collected during routine NHS care. Some clinicians will work in several domains if they have a broader clinical or laboratory remit.

The list of clinical domains described below is representative of the diseases we are now working on in the main programme. It is subject to change at the discretion of Genomics England. In our call for GeCIP domain proposals, we encouraged the applicants to self-organise and make their own domain proposals. This may include domains not mentioned below. They will also be encouraged to propose a UK lead and we will work with applicants to optimise the GeCIP domain as needed.
Figure 5. The data flows that enable the Genomics England Clinical Interpretation Partnership to function.
Table 1 - GeCIP domains.

<table>
<thead>
<tr>
<th>Disease-specific domains</th>
<th>Rare inherited diseases</th>
<th>Functional/Cross-cutting domains</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancers</td>
<td>Rare inherited diseases</td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Hearing and Sight</td>
<td>Education and training</td>
</tr>
<tr>
<td>Cancer of unknown primary</td>
<td>Cardiovascular disease</td>
<td>Ethics and Social Science</td>
</tr>
<tr>
<td>Childhood solid cancers</td>
<td>Respiratory</td>
<td>Electronic health records</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>Endocrine and metabolism</td>
<td>Enabling rare disease translational genomics via advanced analytics and international interoperability</td>
</tr>
<tr>
<td>Glioma</td>
<td>Gastroenterology and hepatology</td>
<td>Functional crosscutting</td>
</tr>
<tr>
<td>Haematological malignancy</td>
<td>Immune disorders</td>
<td>Functional Effects</td>
</tr>
<tr>
<td>Head and neck cancer</td>
<td>Neurology</td>
<td>Health economics</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>Musculoskeletal</td>
<td>Quantitative methods, machine learning and functional genomics</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Skin</td>
<td>Population genomics</td>
</tr>
<tr>
<td>Neuroendocrine tumours</td>
<td>Renal</td>
<td>Stratified medicine</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>Non-malignant haematological and haemostasis disorders</td>
<td>Validation and Feedback</td>
</tr>
<tr>
<td>Pan-cancer</td>
<td>Paediatrics</td>
<td></td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>Inherited Cancer Predisposition</td>
<td></td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarcoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testicular cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper gastrointestinal cancer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This list is correct as of May 2018, see www.genomicsengland.co.uk/about-gecip/gecip-domains for the most up-to-date information.

The GeCIP domains can be led and proposed by researchers, NHS clinicians/healthcare professionals and those training anywhere in the UK. They are not confined to England.
Patients outside the UK cannot be sequenced in the Project, unless full funding is provided by a funder and they join a GeCIP domain and agree to Genomics England Terms and Conditions.

4.4 Accessing data as a Genomics England GeCIP Member
All research data will be de-identified and managed in accordance with the latest guidance.

GeCIP users will be granted access to all data and knowledge held within the Project dataset. Access to the secure virtual Research Environment will be governed via a data access registration and approval process. Each GeCIP domain will have access to its own private shared area of the research environment for data storage and collaboration.

The secure virtual desktop infrastructure will provide the ‘workspace’ for clinical teams, research groups and trainees undertake their work. Work undertaken within the domains is subject to the governance and terms and conditions of Genomics England (see below). Breaches of the governance, or terms and conditions of use, will result in the removal and exclusion of those responsible from the Genomics England Research Environment.

The table below illustrates the structure of a domain.
Table 2.

Groups Who May Access the Research Environment

<table>
<thead>
<tr>
<th>Activity/Group</th>
<th>Key functions and outputs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genomics England Chief Scientist’s Team</td>
<td>• Oversight, informatics and logistics</td>
</tr>
<tr>
<td>GeCIP Steering Committee</td>
<td>• Coordination and management of domains</td>
</tr>
<tr>
<td>Clinical Interpretation including NHS clinicians</td>
<td>• Highest fidelity dynamic reporting system</td>
</tr>
<tr>
<td></td>
<td>• Contribution to Interpretation, Validation and Feedback domain</td>
</tr>
<tr>
<td>Genomics researchers</td>
<td>• Novel genomic discoveries</td>
</tr>
<tr>
<td></td>
<td>• Engagement of international collaborators</td>
</tr>
<tr>
<td>Multiple phenotypic sub-groups</td>
<td>• Deeper phenotyping and sub-analyses</td>
</tr>
<tr>
<td>Analysts and Bio-informaticians</td>
<td>• Novel analytic approaches</td>
</tr>
<tr>
<td></td>
<td>• Development of analytical and reference resources</td>
</tr>
<tr>
<td>Functional characterisation Multi-omics</td>
<td>• Single cell or model functional studies</td>
</tr>
<tr>
<td></td>
<td>• RNA, epigenetics, proteomics</td>
</tr>
<tr>
<td>Trainees and training director</td>
<td>• Research projects and higher degrees through the Genomic Medicine Academy</td>
</tr>
<tr>
<td>Precompetitive industry partners</td>
<td>• Academic-industry collaboration to accelerate application of new findings</td>
</tr>
<tr>
<td>Industry partners</td>
<td>• Industry partnerships to accelerate application of new findings</td>
</tr>
</tbody>
</table>

Note: It is anticipated that precompetitive industry partners will work within the GeCIP domains. All data generated in a GeCIP domain remains available to all.

In certain situations, there may be direct clinical benefit in allowing researchers to access data which could be considered identifiable (for example the use of full postcodes to identify geographical health-related risk factors). In such special circumstances, if the Access Review Committee agrees that access to this data would be appropriate and scientifically justified, this may be made available where appropriate legal agreements and additional safeguards are in place. Explicit provision for this, within this protocol, has been requested by patient representatives on the Access Review Committee.

4.5 The commitment of all data generated to the Genomics England Knowledge Base

Genomics England will encourage and promote an environment of open collaboration. GeCIP members will be expected to comply with this approach to enhance and maximise the value of the Genomics England knowledge base.
In all cases the research results, along with raw data and analytical steps undertaken within the GeCIP domains, must be provided to the Chief Scientist’s team, for commitment to the knowledge base.

Genomics England is committed to delivering a managed research environment and will negotiate with GeCIP members regarding sharing of intermediate research results within the knowledge base. While it is understood that this is a sensitive area, it is hoped that such sharing will serve to accelerate scientific progress, delivering further patient benefits by enhancing feedback to the NHS.

4.6 GeCIP contribution to interpretation, validation and regulation of findings

The GeCIP domains and committees are expected to collaborate with regulators, including E-Quality Management System, National Institute of Health and Clinical Excellence (NICE), Medicines and Healthcare Regulatory Products Agency (MHRA) and NHS England to develop standardised approaches to validate findings from the Project and its legacy. In addition, this collaboration is expected to support the development of systematic approaches to verification of these scientific findings, evaluation of proposed applications on diagnosis and treatment options, and management of impact on commissioning strategies and costs. This joined-up-approach will ensure swift translation of clinically validated research findings into adoption for patient benefit.

4.7 Overarching GeCIP management and governance

The GeCIP Board, chaired by a Genomics England Board member, oversees the governance of GeCIP. Membership will also include a GeCIP lead for the NHS contributors relating to cancer, rare disease and cross cutting domains, as well representatives of major funders, and a representative(s) from the National Participant Panel and from NHS England. Genomics England will be represented by its Chief Scientist. Further details on the governance structure are available at www.genomicsengland.co.uk/about-genomics-england/the-board/clinical-interpretation-partnership-board/.

A GeCIP Steering Committee will be established to ensure the smooth running and transfer of knowledge across the GeCIP domains. The membership will consist of leadership from each disease-facing domain. It will be chaired by the Chief Scientist for Genomics England. The GeCIP Steering Committee will directly report to the GeCIP Board. This committee will include representatives of the public, patients and medical research charities.
5 Feedback for participants
5 Feedback for participants

Feedback of findings as a result of a diagnostic test request will be to the NHS GLH network (or equivalent for other cohorts where appropriate), through web-based tools developed or procured by Genomics England, as well as summary findings being available in a patient Genomic Record developed as part of the Test Order and Management System (TOMS). Each GLH will work with NHS GMS genomic multidisciplinary teams who will make recommendations to the patient’s clinician based on the whole genome sequencing and other genomic test results. This will fall under usual processes for clinical governance.

5.1 Enhanced interpretation and handling of findings from the research environment

We have converted the GeCIP domain on ‘Validation and Feedback’ to ‘Enhanced Interpretation’ and they are developing a plan connecting the GeCIP research endeavour into the clinical service. Each GeCIP domain will be connected via an Enhanced Interpretation Domain member. The GeCIP team, working with the GeCIP domains, will alert the Enhanced Interpretation Domain to new findings that may be of potential clinical utility and benefit to participants. Where this is the case, this will be assessed and these findings may contribute to reporting from the Genomics England Interpretation Pipeline and the generation of a new whole genome analysis for the NHS GMS.

The decision on whether this analysis is taken forward to validation of key diagnostic findings, regardless of their origin, will be led by the new GLHs (including the Wales and NI GMC) and the new NHS GMS. Results of validation tests will continue to be shared with Genomics England to enhance the value of the Data Centre.

It is our goal to use this mechanism to improve the relevance of whole genome sequencing findings for healthcare during the life of the Project. The Project/GeCIP is committed to regularly publishing peer-reviewed updates on the current state of knowledge in this area. In preparing the Genomics England Feedback Policy, we took full account of all relevant legal and ethical principles including contemporary research and the advice of patients. This has also been informed by Professor Mike Parker’s letter to the Chief Medical Officer from the 100,000 Genomes Project Ethics Advisory Working Group (see www.genomicsengland.co.uk).

GeCIP will be operated by the Office of the Genomics England Chief Scientist, with two major primary functions:

(i) its role with regard to research and the research community (described above) and
(ii) responsibility for supporting clinical validation of genetic variants of expected pathogenicity.

Diagnostic capability to detect pathogenic variants is expected to evolve. Any results generated within the research environment could be fed back to diagnostic clinical scientists and others for consideration for diagnostic reporting.

5.2 Policy for main findings, secondary findings, and incidental findings, and feeding back to clinicians and patients

Information on feeding back of clinically relevant findings to clinicians and patients is available at www.genomicsengland.co.uk/taking-part/results. The Project will take account of the evolving
policy and academic debates in the area and has been influenced by these in respect of its current formation.

As in the main programme, types of results sought by the Genomics England bioinformatics pipeline will continue to include:

**Known or pathogenic variants or driver mutations** directly connected to the main disease that led the patient to take part in the Project and that are clearly actionable.

**Additional findings.** If the clinical test involves WGS, a very limited number of looked-for known, pathogenic mutations of high clinical relevance, confined to a very limited list. This will be more limited than that used by the American College of Medical Genetics. It will be possible for patients to opt-out of the feedback of findings of high clinical relevance. The list of findings to be sought in children will not include conditions where no action is indicated before reaching adulthood, to allow children to take their own decision on receiving these findings once they attain capacity to do so. Prospectively, this will be implemented as part of an evaluation framework within the context of the new NHS GMS.

**Parental carrier status** in cases of rare disease due to bi-allelic germline mutations. It is feasible that this programme will identify double parental carrier status or X-linked maternal carrier with high-risk of a reproductive consequence. These results will be assessed for suitability for diagnostic reporting by an NHS clinical scientist or equivalent.

<table>
<thead>
<tr>
<th>Type of finding*</th>
<th>Description</th>
<th>Nature of the information to be fed back</th>
<th>How feedback will happen</th>
<th>Approach to consent or refusal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertinent finding (also known as a primary finding). Found in the research environment</td>
<td>A pertinent (primary) finding is relevant to the explanation, main diagnosis or treatment of the disease for which the patient was selected for testing.</td>
<td>To be reported as a pertinent (primary) finding, mutations must be confirmed by a clinical service. Information provided to the clinical service will include categorising results as 1) 'Known to be Pathogenic' (KP) i.e. sequence variation is previously reported and is a recognised cause of the disorder. 2) Mutations that are 'Expected to be Pathogenic' (EP) i.e. sequence variation is previously unreported and is of the type which is expected to cause the disorder.</td>
<td>Pertinent (primary) findings will be given to the referring clinician or clinical team by the 100,000 Genomes Project for discussion with the patient after the NHS Genomic medicine Service has validated these findings.</td>
<td>Where the data and sample source are a clinical service, the service is expected to define the return of results approach under clinical governance. For example, in the NHS GMS it is currently expected that Somatic cancer findings will be reported back without delay but pertinent germline findings will require consent. There may also be revaluation of negative results under clinical consent. Where reporting is not under clinical governance the continuation of existing research-based return of results is expected to apply, thus ensuring continuity of the offer to participants in both setting. Where testing is under a clinical service, patients may refuse to allow their data to enter into the research environment.</td>
</tr>
</tbody>
</table>
Incidental findings are those that occur unexpectedly in the course of analysis, which could have implications for a patient’s health or care. Incidental findings identified during the course of research will not be fed back to patients or clinicians unless there is an exceptional reason for doing so. These might be considered by the Genomics England Science Advisory Committee or Ethics Advisory Group if advice is required to direct decisions about feedback. Incidental findings that occur in the context of a diagnostic analysis will be managed according to standard clinical practice initially.

**Table 3.** Summary of 100,000 Genomes Project policy on feedback of findings:
<table>
<thead>
<tr>
<th>Type of finding*</th>
<th>Description</th>
<th>Nature of the information to be fed back</th>
<th>How feedback will happen</th>
<th>Approach to consent or refusal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Secondary finding</strong> (additional looked-for findings of healthcare importance). In patients having Genome Sequencing</td>
<td>A secondary finding is an additional, looked-for health related finding, that is not pertinent to (or a primary cause of) the main condition. It may be found in addition to (or in the absence of) any pertinent finding.</td>
<td>NHS England will evaluate the impact of looking for genomic findings that are known to cause serious conditions for which there is good evidence that knowing about them could influence healthcare. They will build on the limited list of relatively rare conditions, in the 100,000 Genomes Project and adapt this list as more evidence accumulates. The current list will be available on the website</td>
<td>Participants will be asked whether they would like these secondary findings to be actively sought. If they consent to this, information relating to secondary findings will be looked for and given to the referring clinician or clinical team for discussion with the participant. (Without this consent these secondary findings will not be actively sought.) Following positive or negative confirmation regarding these secondary findings, a health professional will feed back to the participant on these results. Some variants in this gene list may not yet have sufficient evidence for their clinical impact to be known, or clearly predicted. These variants of uncertain significance will not be reported. An important evaluation aim of the 100,000 Genome Project and the NHS Genomic Medicine Service and beyond is to generate evidence about the clinical relevance of new findings. Our understanding of the clinical significance of a secondary finding will change over time as more evidence is gathered.</td>
<td>Consent for the feedback of these secondary findings will be by opt-in to feedback. Patients who do not wish to receive information about these findings are free to refuse to consent. Participants can opt-in to consent to the list(s) of identified conditions to be looked-for at the time of consent, plus, if they wish, to findings made as that list extends. This will permit results regarding other conditions that meet this criterion in future to be looked-for and fed back.</td>
</tr>
</tbody>
</table>

Please note: The Genomics England approach to findings relating to adult onset conditions in children will be in accordance with the BSGM policy on genetic testing of children” i.e. only the mutations in genes that are known to cause childhood-onset disease will be looked for in the case of minor participants.

---

** This list is based upon that proposed by ACMG plus subsequent expert review at Genomics England.


See also ACMG Updates Recommendation on “opt Out” for Genome Sequencing Return of Results, April 2014. Available at: [https://www.acmg.net/docs/Release_ACMGUpdatesRecommendations_final.pdf](https://www.acmg.net/docs/Release_ACMGUpdatesRecommendations_final.pdf).

<table>
<thead>
<tr>
<th>Type of finding*</th>
<th>Description</th>
<th>Nature of the information to be fed back</th>
<th>How feedback will happen</th>
<th>Approach to consent or refusal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carrier status</td>
<td>Under certain circumstances carrier status may affect future children.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Autosomal recessive. Where both parents participate, we will be able to identify a limited list of double carrier states where knowledge might affect future family planning.</td>
<td>NHS England will evaluate the impact of looking for genomic findings that are known to cause serious conditions for which there is good evidence that knowing about them could influence healthcare. They will build on the limited list of relatively rare conditions, in the 100,000 Genome Project and adapt this list as more evidence accumulates. The current list will be available on the website.</td>
<td>Participants will be asked whether they would like these carrier states to be actively sought. If they consent to this, information relating to carrier states will be looked for and given to the referring clinician or clinical team for discussion with the participant. (Without this consent these carrier statuses will not be actively sought.) When either positive or negative results are confirmed regarding these looked-for findings, a health professional will feed back to the participants.</td>
<td>A list of conditions for opt-in looked-for carrier status. For double carrier of recessive feedback will be undertaken for those who opt- in, provided both parties in the couple consent to seeking and return of these results as a couple. Or a woman carrying an X-linked disorder consents to opt-in to feedback.</td>
</tr>
<tr>
<td>Incidental findings</td>
<td>A sub-category of additional findings that are not actively sought. Also described as ‘unsolicited’ findings****</td>
<td>Incidental findings found in the research resource will only be utilised in the clinical setting once they are assigned to the list of secondary findings above.</td>
<td>Incidental findings will usually not be sent to clinicians or patients by Genomics England.</td>
<td>The policy on not feeding back incidental findings will be explained to the patient at the time of consent.</td>
</tr>
</tbody>
</table>

**** Anneke L notes: Although these terms have no clear definitions and their meanings may be more or less relevant to the different parties involved. For example, a patient may find a secondary finding unexpected, but a laboratory worker analysing a whole genome should expect to possibly find anything.
Consent process to receive additional/secondary looked-for findings and carrier status*

Individual adult participants (or their consultees or equivalent in the form of advice), or a suitable adult (in regards to child participants) will be asked to give their explicit consent to permit additional findings and to receive the results of these. Within the NHS GMS, these will be discussed with the patient or their nominated representative by the clinician requesting the test, or a suitably trained colleague acting on their behalf. For other cohorts, these will be discussed at the point of consenting or when a consultee’s advice is sought.

With regards to the lists of secondary and carrier status findings, consent will be given to ‘any other conditions that meet these criteria over the life of the Project as these lists evolve.

These lists will be regularly reviewed by NHS England and updated by experts to guide this policy. Changes to the shortlist of conditions would require the support of NHS England and Wales who would need to fund clinical support to patients.

The feedback timeframe

The new NHS GMS will be responsible for determining the timeframe for return of results within the clinical service. For results being returned outside of the NHS GMS the default expectation is comparable feedback times to those for the NHS GMS.
6 Programme delivery and management
6 Programme delivery and management

6.1 Project management

For the NHS GMS and broader genomic developments involving the NHS, a Partnership Board has been established to ensure visibility and co-operation between NHS England, Genomics England and NHS Digital at the highest level. In addition, a Data and Informatics Board convenes monthly to specifically oversee matters relating to the informatics delivery.

The Partnership Board is informed and takes in account other organisation specific governance arrangements.
7 Informatics architecture
7 Informatics architecture

Clinical, laboratory and the health data flow from NHS and other organisations into the Genomics England data management section will be de-identified prior to storage within the Research Environment. The de-identification process is in line with the latest guidance from NHS Digital and the Information Commissioner’s Office.

In the NHS GMS, standard NHS approaches to identifiers will be adhered to. For the research environment, these will be linked to identifiers that enable us to ensure that we continue to return relevant findings from research activity.

7.1 Information governance and security

Patient confidentiality and protection is a key cornerstone of the Project and its legacy. We wish to promote an active Clinical Interpretation Partnership and encourage appropriate and qualified users into the data infrastructure.

A key feature of the Genomics England programme is that individual level data will not be ‘released’, but will instead be analysed within a secure, monitored environment akin to a reading library. That is, where books cannot be taken away but must be read in situ in a monitored environment. The Genomics England ‘Airlock Policy’ ensures that the movement of data in, and summary results out of the Research Environment occurs in a controlled and supervised manner, with the goal of facilitating research and discovery whilst maintaining the security of the datacentre.

To protect patient confidentiality, access to this environment will be granted only for specific, approved purposes in accordance with informed consent. Any attempted use beyond the specified purpose may lead to exclusion and possible legal action, where appropriate.

Genomics England will require:

- An appropriate legal gateway for analysis (for Genomics England, the legal gateway is valid consent based on an ethically approved protocol) from each participant.
- Simple signed data sharing agreements will be expected between all parties accessing and using data as part of the Genomics England pipeline. Genomics England will have a simple electronic agreement system which all users will sign who wish to access the data.
- This agreement will include a description of our rigorous data access, sharing and acceptable uses procedure and approval to ensure compliance with governance requirements across the pipeline, and safeguard data confidentiality and patient privacy.

The list below outlines the activities, checks and balances required to ensure Genomics England is processing patient data in an appropriate way.

- Delivery of the service model, whereby customers cannot export raw data (only summary results) and data delivered for research use is de-identified.
- Delivery of processes for the achievement of valid consent and accompanying literature for all Genomics England data subjects.
- Including seeking REC approval for the protocol and patient information sheets and consent.
• Delivery and active management of signed data sharing agreements between Genomics England and all its data suppliers, and Genomics England and its users.
• Delivery of NHS Information Governance Toolkit assessment (or its replacement, due to be delivered in 2018).
• Delivery of privacy impact assessment and equality impact assessment, and accompanying action plans.
• Delivery of information governance continuous improvement plan, and training and awareness for Genomics England staff.
• Delivery of staff contracts with explicit clauses relating to employee responsibilities to safeguard data integrity and security.
• Where appropriate policies and Standard Operating Procedures (SOPs), based on guidance from the Information Commissioner’s Office (ICO) that set out the ways in data may be accessed, handled and disclosed within the secure Data Centre.
• Data access request log and process, and data transfer logs relating to all identifiable data – reviewed regularly to ensure adherence to SOPs
• Delivery of clear data models for use and plans for effective data management.
• Within the research-accessible part of the infrastructure, the ability to link back data. This is to enable updates of secondary data or further information and to ensure the ability to inform patients of relevant findings is necessary.
• Tools for enhanced audit logging and processes to verify customer use of the data and take action if non-compliance is detected.
• Standard OGC ITIL compliant processes for service management, including management and control of live service incidents.

Policies on data access, data integrity and security controls (including encryption of both data and mobile devices, backup, firewalls, anti-virus protection), audit and verification procedures; and formal change management of all security documentation will continue to be kept under review and be developed in line with NHS standards of good practice.

All data transfers and data access requests will be logged and subject to regular scrutiny by the Service Delivery Team. Escalation procedures will be in place to manage non-compliance if detected, based on the data sharing agreements signed by users (or internal staff/supplier contracts in the case of an internal breach).

The Research Environment will provide clinical researchers with managed, audited access to data and computing resources. Activity logs will be analysed on a regular basis, with any exceptions flagged to the Service Delivery Team for further investigation and escalation as required. Additionally, the Genomics England Board will ensure that the Chief Scientist, Chief Information Officer, Chief Operating Officer and Caldicott Guardian establish adequate procedures for documentation, tracking, monitoring and reporting for overall process of data sharing.

As part of its assurance and approvals plan, Genomics England will seek ethics approval for the research database itself, complete the NHS Information Governance Toolkit (or its replacement) on an annual basis and maintain a continuous improvement plan for information governance. In addition to the above IG standards, Genomics England has adopted a more general approach to gaining the appropriate accreditation for its pipeline and is currently also in the process of gaining
via the UK Accreditation Service, ISO 15189 for the clinical bioinformatics service. Data will be held by Genomics England at more than one data centre in England.

### 7.2 Data access, sharing and acceptable uses of information from participants

The Project’s consent discussion and patient literature outlines the plans around data access, sharing and acceptable uses in addition to security, third party and participant access requests to data. This will be accessed in a de-identified format by clinicians, academics and industry in the UK and overseas. The policies relevant to this can be accessed via a Genomics England secure portal.

Genomics England takes data security and patient privacy extremely seriously. It will take action where a breach, or near breach, is proven. Penalties for non-compliance include Genomics England’s revocation of user access, organisation access and reporting the offending activity to the appropriate regulatory authority. We will where possible, notify individual participants affected if we discover data breach notifications, enabling them to exercise their ‘right to object’ to further processing of their personal data.

All policies, procedures and literature relating to data security and privacy shall be formally placed under change control. Formal policies relating to purposes and uses will be subject to discussion and consultation with stakeholders.

All users must act, at all times, in accordance with the terms of Genomics England’s informed consent policy, procedures and literature.

Genomics England welcomes applications for use of its datasets from the commercial, academic and clinical communities, and is keen to create an environment through the Genomics England Clinical Interpretation Partnership (GeCIP) to enable different kinds of users to work together to share and build new knowledge about the data that can be translated into new diagnostic and treatment options for patients.

The Project has commissioned participant, patient group and health professional surveys and interviews around issues of data sharing and access. In addition, in relation to these specific issues, stakeholder meetings with a series of groups concerned with issues of privacy and consent have taken place during summer 2014. The views fed back in respect of collection, handling and sharing of data in the Project have been incorporated. In 2016, a consent survey was undertaken which has informed updates to this protocol and methods of communication to participants about the Project.

**Data Protection**

The General Data Protection Regulation (GDPR) (EU) 2016/679 is a regulation in EU law on data protection and privacy for all individuals within the European Union.

The introduction of GDPR and the forthcoming Data Protection Bill may have particular impact on research programmes. The genomics research programme discussed in this protocol awaits clarification on the interpretation of the law and policy statements from various bodies.
As with most Health and Social Care systems, the introduction of GDPR necessitates that the NHS GMS await clarification on a number of key terms and concepts. One prominent example is the term ‘de-identification’ which has been used within this document to denote ‘compliance with the Information Commissioner’s Office (ICO) Anonymisation Code of Practice’, whether that is the current or future iterations.

All Genomics England systems and processes are being reviewed against GDPR rules and where necessary will be updated for compliance. Future updates to this protocol will define any necessary compliance activities.

7.3 Partnerships to ensure patient recruitment, sample and data acquisition
Samples and data will be provided primarily through the NHS GMS (details to be established by NHS England) and through cohorts (details to be negotiated with each cohort owner).

7.4 NHS England requirements and specifications – 100,000 Genomes Project and NHS GMS
There are a number of activities required to enable NHS England to deliver aspects of the pipeline described above. These are described or specified in further detail below. Delivery of the Project in Northern Ireland, Wales and Scotland (which is under a separate protocol) is managed through separate Memorandum of Understanding, Services Agreement and other supplementary agreements.

7.4.1 NHS Genomic Medicine Centres (GMCs)
NHS England have established NHS GMCs across England following a rigorous procurement, contracting, accreditation and performance management process. These centres will continue in an evolved form to operate to support the new NHS GMS.

7.5 NHS England requirements and specifications – Genomic Medicine Service
During the first half of 2018, NHS England is procuring (through standard NHS processes) a network of GLHs as one of the key elements of the evolution of the Project to the complete NHS GMS. These organisations will be charged with the delivery of genomic testing services to their relevant region and/or nationally, including the provision of data and samples to Genomics England, operating under a partnership agreement to procure and provide the diagnostic whole genome sequencing requirements.

The GLHs will be responsible for the provision of sufficiently high-quality samples and data to enable whole genome sequencing in accordance with Genomics England’s ISO-accredited standards and processes (when achieved) and in line with agreed NHS England contractual obligations.

NHS GMCs will also evolve to become part of the NHS GMS, along with clinical genetics services and other activities around mainstreaming of clinical genetics and will include relevant cancer services using genomic analyses to direct clinical management decisions.
The Central Biorepository function will potentially be provided in several places; by the NHS GLHs/GMCs for the clinical diagnostic service; and by the Genomics England central biorepository for other Genomics England activities.

Throughout the course of the Project, there has been ongoing work to reduce the requirements for DNA in order to improve the viability of WGS in a clinical service. This has been communicated to NHS GMCs and will continue to be communicated within the NHS GMS through sample handling guidance documents, available at www.genomicsengland.co.uk and through other mechanisms being put in place by NHS England.

7.5.1 Sample and DNA acquisition and logistics for NHS Genomic Medicine Service
Sample acquisition and DNA extraction specifications for the NHS Genomic Medicine Service are depicted below.

After a test request is made on the Test Ordering and Management System (TOMS), primary sample tissue and blood is collected according to existing NHS standards and practices and despatched to the GLH. The receiving GLH will validate the test request and received sample type, and extract DNA to the specifications of the NHS GMS guidance. DNA extracted for all elements of a test (e.g. tumour and germline for diagnostic cancer whole genome sequence) will be stored locally within a GLH/GMC NHS Biorepositories or the Genomics England Central Biorepository.

7.5.2 Labelling of samples
Each biological sample sent to the NHS Biorepositories or the Genomics England Central Biorepository from a GLH should be preceded by a sample despatch message identifying the sample as labelled. It should also include additional relevant sample-specific data such as volume, concentration etc.

7.5.3 DNA delivery to sequencer (logistics)
DNA samples extracted in GLHs may be plated and/or despatched in tubes directly to the sequencer after approval of the plating/sample proposal, to assure appropriate sample placement and/or provision. Equivalent processes will be in place for other sample and data sources than the NHS GMS.

7.5.4 Sample and DNA acquisition and logistics for WGS
Sample acquisition and DNA extraction specifications for cancer and rare disease are depicted below.

DNA extracted from blood and tumour must be sent together to a specified biorepository, following confirmation that clinical data is available that meets Genomics England and/or NHS England requirements as laid out in relevant Genomics England and NHS GLH SOPs.

Throughout the Project, it is expected that Genomics England and NHS England will work in partnership to identify and implement changes to the diagnostic pathways inclusive of molecular pathology within the accredited GLH/GMC centres as part of the NHS GMS to enhance sample quality, in order to optimise the Genomics England pipeline. It should be noted that some of the requirements may evolve.
Genomics England will work with the NHS GMS inclusive of GMCs/GLHs GMCs to finalise the following dataset and collection tool:

- DNA source – germline/tumour
- Standard Operating Procedure version(s) used for collection, extraction, QC and logistics.
- Tumour type (if cancer– primary/recurrent/metastatic)
- Topography and Morphology (if cancer)
- Tumour cellularity percentage (if cancer)
- DNA concentration (nanogrammes/microliter)
- DNA volume (microliters)
- DNA QC metrics (to be finalised with sequencer)
- Genomics England identifier for data subject (site ID, local patient ID (NHS Number), sample ID)
- Gender and ethnicity
- Date of birth
- Pedigree structure and affectation status (rare disease)
- Version of Consent and Patient Information Sheet used
- Syndrome or disease name
- Named site contact and email (to verify receipt of samples by collection hubs, for queries etc.)

7.5.5 **Key Performance Indicators (KPIs)**

Key performance indicators will be recorded to monitor the process and also to enable the identification of variables that affect sequence quality. These will be agreed within the NHS GMS.

7.5.6 **Data from sample acquisition site**

Local sample metadata will be required to be submitted in advance and alongside the DNA samples, to enable sequencing and annotation. Data will be submitted in accordance with the NHS GMS requirements or equivalent.

7.5.7 **Data from national NHS and other sources**

Genomics England expects to collect other health data on its consented patients into its data centre, to link outcomes data to the WGS and clinical data already held. This may involve ongoing data delivery from other organisations, including but not restricted to: NHS Digital, the CPRD or other sources of primary care data, Public Health England, disease registries, screening programmes and patient communities.

All organisations operating within the pipeline need to provide monitoring and reporting functionality to facilitate the tracking of samples and data end-to-end.
8 Genomics England data access and acceptable uses
8  Genomics England data access and acceptable uses

Policies for data access, sharing and acceptable uses have been developed in line with the Medical Research Council (MRC) Policy and Guidance on sharing research data from population and patient studies. These will be based on similar policies from the Wellcome Trust Centre for Human Genetics, and input from the Information Commissioner’s Office and the Genomics England Ethics Advisory Committee and patient groups.

8.1  Users of the Project data
The data access and acceptable uses criteria have been summarised in this section.

Access to data will be controlled according to the provisions of the Data Access policy and all users will sign a Genomics England data access agreement.

8.1.1  Patient access
Genomics England has published on its website a privacy notice that explains how it will respect the rights and privacy of all data subjects.

8.1.2  NHS healthcare teams
Findings will be fed back securely to the identified clinician and/or team responsible for caring for the patients via the NHS GMS/GLHs. These findings will contain patient identifiable data (see above).

8.1.3  Academic researchers and trainees
They will either be a Genomics England Clinical Interpretation Partnership (GeCIP) user or if not, they will pay to access the data.

8.1.4  Commercial researchers and Industry engagement
This project also covers commercial research. The same rigorous criteria will be applied to data access for industry.

Industry engagement is managed through collaborative fora and direct engagement with companies. This provides a platform for collaboration and engagement between Genomics England, industry partners, academia, the NHS and the wider UK genomics landscape and is open to a range of companies world-wide. The main aim is to bring together multidisciplinary expertise to maximise the potential of the Project dataset and to assure that the main Project aim of bringing benefit to patients is perpetuated well beyond the Project end date.

In the first instance activities will focus on research to improve diagnoses for the patients (via research discoveries or tool improvement); to increase availability of potentially life-saving clinical trials; and to drive drug delivery from development pipelines to the healthcare.

8.2  Data access and sharing for the Project
The purpose of the infrastructure is to provide maximal access to researchers, the NHS and those in training, enabling managed access to the data assets created by the Project. The infrastructure will
be designed to facilitate the sharing and re-use of data and compute resources, and to promote scientific collaboration in clinical genomics research. Software infrastructure – models, interfaces, and tools – will be provided for the generation of ‘analysis ready’ datasets.

All requests for data access will be subject to the following considerations:

- Protection of data subjects (honouring commitments made to them, acting within the scope of consent and according to conditions of Research Ethics Committee approval).
- Provision of a signed Genomics England data access agreement to the Access Review Committee (see Information Governance above).
- Prioritisation of access according to resource availability.
- Facilitation of high quality research.

Access to the data and compute infrastructure will be subject to approval by the Genomics England Access Review Committee.

### 8.2.1 Data sharing requirement

For the purposes of this document, data held shall be defined as either:

1. The data held within the Genomics England Data Centre about participants within the Project (service data), or
2. The data held by Genomics England relating to its business, its customers and users, its staff etc. (corporate data).

It is the core business of Genomics England to share service data, within an agreed governance framework, in order to deliver access to treating clinicians which may be identifiable for NHS use (see above). It is also part of our core mission to provide access to researchers and scientists. Such data will be de-identified, unless there is a legal basis in place for the disclosure of identifiable information.

Furthermore, Genomics England is bound, through various legislative and regulatory instruments, to deliver data or access to specific requestors for specific purposes e.g. to share data requested under the General Data Protection Regulation, or to deliver the results of financial audits to regulators. For these sorts of requirements, both corporate data and service data might be shared, anonymised or aggregated unless there is a legal basis in place for the disclosure of identifiable information.

As previously noted, sharing of data for prescribed purposes is key to the Genomics England business model. However, decisions on data sharing must always be assessed against the risk to
data confidentiality and the privacy of data subjects. All decisions relating to data sharing should be made considering the policy provisions enshrined here.

Where risks to data sharing fall outside of the tolerances set out on the agreed SOPs, Genomics England shall work with its legal counsel and information governance and data security leads, to deliver a transparent decision-making process and associated assurance, validation and reporting.

8.2.2 Access to service data
All data held within the Genomics England Data Centre that relates to the Project data subjects is considered to be service data.

Service data will be made available within an agreed governance framework in two ways:

i) With internal staff (under substantive contract of employment) within Genomics England, in order to check data quality and integrity; to undertake agreed cleansing activities; to deliver initial bioinformatics analytics on the data; and to undertake other monitoring, audit and service improvement activity. It is noted that internal access to all data held shall be controlled, monitored and reported upon. Access to identifiable data, which is held separately, must be explicitly logged and approved by the nominated Genomics England Information Governance Team.

ii) With external users and consumers, as follows:

a. In the form of proactive publication of de-identified aggregated information as summary metadata.

b. Delivery of access (within the Genomics England Data Centre) to agreed datasets for approved users, including scientists undertaking research into whole genome data. Data will be de-identified unless a legal gateway exists for access to identifiable information.

The aggregation of rare and cancer genomic data at international levels gives scope not only to resolve disparities in clinical interpretation\textsuperscript{xx} but also to place patients’ data in the correct phenotypic and genomic contexts, including with respect to ethnicity. \textsuperscript{xxi} The Project presents a unique opportunity to optimise patient benefits, while minimising the risks of sharing potentially identifiable personal data, as is commensurate with global initiatives for data availability and under the standards laid out by the Global Alliance for Genomics and Health.\textsuperscript{xxii}

Summary-level data, including the publication of allele frequencies, must be made available to clinical and research communities to aid genomic analyses. Individual-level data can be shared where there is the potential for individual clinical benefit. Further details can be found in Airlock documentation.

In the area of case-solving, routine clinical practice and governance applies.

8.2.3 Corporate data sharing
Corporate data is defined as data that is held by Genomics England that relates to the work and operations of the business, including its organisation, its people, its performance and its decision-making. Certain corporate data may be shared, within an agreed governance framework, in order
to meet statutory and regulatory requirements. This includes the proactive publication and maintenance of information about the operations of the business, in line with the provisions of the Freedom of Information Act.

8.3 Acceptable research uses
All users and uses must be consistent with the terms of informed consent policy, procedures and literature pending REC approval.

8.3.1 Types of purposes
The following list of purposes will be used by Genomics England to classify the type of work its users want to undertake. Under the terms of ethics approval, Genomics England plans to operate an internal process to assess applications and grant access to data that relates to any of the purposes below.

<table>
<thead>
<tr>
<th>Definition</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical care</td>
<td>Use of data to directly diagnose / treat a patient.</td>
</tr>
<tr>
<td>Hypothesis driven research and development in health and social care - observational</td>
<td>Hypothesis driven review and analysis of data collected within the Genomics England data centre.</td>
</tr>
<tr>
<td>Clinical trials feasibility</td>
<td>Queries on the broad location and numbers of patients eligible to participate in interventional research project.</td>
</tr>
<tr>
<td>Hypothesis driven research and development in health and social care - interventional</td>
<td>Hypothesis driven review and analysis of agreed cohorts of patients within a research study.</td>
</tr>
<tr>
<td>Non-hypothesis driven R&amp;D - health</td>
<td>Review and analysis to identify associations between data and variables - to improve our understanding of the causes of disease.</td>
</tr>
<tr>
<td>Non-hypothesis driven R&amp;D - non-health</td>
<td>Use of the data by data scientists to test the effectiveness of tools and models for data analysis.</td>
</tr>
<tr>
<td>Public health purposes</td>
<td>Work to gain a population level understanding of the prevalence of disease and corresponding health protection actions where possible.</td>
</tr>
<tr>
<td>Other health use - clinical audit</td>
<td>Use of the data to assess whether clinical standards are met.</td>
</tr>
<tr>
<td>Other health use - commissioning / commissioning policy</td>
<td>Use of Genomics England data to inform decision–making by any relevant commissioning body / organisation developing commissioning policy. Trust use to undertake local planning and administrative tasks.</td>
</tr>
<tr>
<td>Subject access request</td>
<td>Request by the data subject regarding the data Genomics England holds about them.</td>
</tr>
<tr>
<td>Tool evaluation and improvement</td>
<td>Use of the data to validate, improve and deliver new annotation tools for WGS data.</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Interpretation and validation of the Genomics England Knowledge Base</td>
<td>Use of the data to interpret annotation findings and validate results for use in a clinical context.</td>
</tr>
<tr>
<td>Education and training of health and public health professionals</td>
<td>NHS professionals and others learning how to analyse, interpret, and apply genomic medicine.</td>
</tr>
<tr>
<td>Deeper phenotyping</td>
<td>Gaining further information on patients with particular genetic results.</td>
</tr>
</tbody>
</table>

### 8.3.2 Uses that the Project will decline

These types of purposes might be proposed by participants or third parties. They will typically be refused outright following consideration. This will be by the Genomics England Informatics Team and the Genomics England Access Review Committee who will decide upon approval or rejection on a case-by-case basis.

Additionally, all requests that are required by court order will be notified to the Genomics England legal counsel and the Executive team.

The Genomics England decision-making process on all occasions shall be documented and transparent and involve external bodies (e.g. REC) where necessary.

- Paternity testing and level of relatedness testing (though participants can request their data and, as such, if several family members make this request and take the data to a third party to analyse, it is conceivable that the data can be used in this way).
- Parental request for child’s data once the child reaches 16, where either the participant assents or dissents.
- Requests in the form of Court Orders will be referred to Genomics England’s Legal Counsel as promptly as possible, so that all representations may be made to the court, for example to limit the information requested.
- Uses requiring linkage to employment records, tax records, benefits records or personal life insurance records for non-scientific or non-healthcare related purposes.
- Uses requiring linkage for personal insurance or forensic purposes.
- Purposes that might lead to discrimination against a person or a group of people, based on genetic/ genomic characteristics.
9 Genomics England data ownership and intellectual property
9 Genomics England data ownership and intellectual property

Genomics England has received legal advice regarding intellectual property. This recommends that Genomics England owns the combination of the whole genome sequence and the clinical data for the entire dataset from the Project. In addition, Genomics England owns any new intellectual property generated from the data, but we will license this to third parties on favourable terms.

There are clear reasons why this is essential:

- It ensures that Genomics England Clinical Interpretation Partnership (GeCIP) investigators can collaborate in academic/NHS partnerships and academic industry partnerships without concern for the intellectual property being generated.
- The ready licensing with the capability to include all inventors offers a fair approach to potential intellectual property.

9.1 Genomics England publication policy

Genomics England encourages publication through our publication policy and process.

Acknowledgements in all publications will recognise the contribution of the Department of Health and Social Care, NIHR and any other GeCIP funder with the following form of words: "Genomics England is a wholly owned company of the Department of Health and Social Care and this programme was made possible by the National Institute for Health Research, NHS England, Public Health England and Health Education England."

Other GeCIP funders must also be acknowledged.
10 Consent
10 Consent

Achieving informed consent in the context of clinical genomics is recognised to present important practical challenges and requires careful ethical consideration. This is also true for the design of the 100,000 Genomes Project and NHS GMS, an initiative combining standard clinical care with research and translational medicine aims.xiii,xiv The Project will follow established legal and regulatory standards for seeking the informed consent of its participants, or those who could consent on their behalf. It will follow applicable legal and regulatory standards around the potential or actual involvement of adults who lack capacity, including seeking the advice of appropriate consultees regarding their participation, including in regards to participants who join the 100,000 Genomes Project and thereafter are deemed to have lost capacity.xv

The earlier stages of the Project are now generally recognised as good-practice approaches to obtaining consent. Building on this and the latest guidance for the NHS GMS we will continue to iterate and develop our approach.

This has also been informed by the Chief Medical Officer’s Report, ‘Generation Genome,’ (see https://www.gov.uk/government/publications/chief-medical-officer-annual-report-2016-generation-genome), published in July 2017. Professor Mike Parker’s letter to the Chief Medical Officer from the 100,000 Genomes Project Ethics Advisory Working Group (now renamed the Genomics England Ethics Advisory Committee) sets the standards which we continue to uphold. This can be found on our website: www.genomicsengland.co.uk. Professors Mike Parker and Anneke Lucassen have also provided guidance in the form of a letter outlining principles on which to base the consent model for the NHS GMS.

10.1 The process for consent in the Project

In the NHS GMS, the patient will be given the choice of germline genomic testing which includes the opportunity for them to contribute their data and samples to a research resource at the point at which they have the test. For patients having somatic cancer testing it is envisaged that consent for research may happen before or after this testing to best suit the needs of the patient. In conventional terms, as in the current 100,000 Genomes Project, a broad consent model is proposed whereby permission is given for future research, the exact nature of which may, as yet, be unknown.

The materials supporting the consent process that will be presented to the patient will be layered; a minimum level of critical information will be made available with access to other more specific and detailed information as required by the patient.

Process for consenting a patient:
In circumstances where it is not appropriate to offer the choice to participate in research (for example unconscious patients, urgent tests required in a seriously ill child etc.) the offer of a genomic test will be a clinical decision and the choice to take part in research will be offered later when appropriate. The offer of the choice to take part in research is integral to the NHS GMS and will be audited at the hub level.

More detailed process maps are available in Appendix 6.

Patients under the care of the NHS in England will be referred by their treating clinician for invitation to join the Project because:

a. they have a (suspected) rare disorder or certain forms of (suspected) cancer and joining the programme may reveal important information about their health. Or
b. they are undergoing any genomic test found in the NHS England Genomic Test Directory
c. they are part of a cohort who have had samples and data taken for research or as part of clinical care, but outside of the funding and structures of the NHS Genomic Medicine Centres (see section 4). In such cases, they may also be consented under a separate consent model, but this should be aligned with that of the Project (e.g. the Scottish arm of the 100,000 Genomes Project, which is under a separate protocol)

Eligible relatives of probands in the above categories may also be invited to join the Project to inform research regarding the health of the proband. Deceased participants may be included with the support of their treating clinicians (or their relatives), where appropriate phenotypic information and DNA samples are available and appropriate consents are given. His or her relatives may also join the Project in order to gain information about the deceased proband’s health condition.
Research participants agree to:

- Deposit data (and samples) for use in approved research according to acceptable uses in linked, de-identified format.
- Re-contact to invite to further research, to ask for further data or samples, or offer to invite to further research including clinical trials.
- The return of clinically applicable research results – i.e. potential individual benefit from research participation.

As in previous phases of the Project, patients can change their choices over time (discussed below).

10.1.1 The consent form and patient information literature

Drawing on relevant guidance and exemplars of good practice, the participant materials (i.e. both digital and hard copy versions of letters of invitation, Patient Information Sheets, and assent and consent forms) have been developed in accordance with the key principles in the Key Ethical Principles document and Ethical Governance Framework, and with the advice of the Ethics Advisory Committee, with comments from the Science Committee, and other stakeholders and the appropriate guidance.

The consent discussion with participants will draw attention to key elements of the Project that may be regarded as having particular ethical, legal or social implications. This discussion will include seeking explicit consent to:

- Linked access to participants’ health records in perpetuity.
- Access to deidentified participant information and samples by third parties with the appropriate permissions (who may be based in the UK and overseas) and which includes commercial (‘for-profit’) companies.
- Agreement to recontact by their clinical team, in order to permit invitations to participate in further studies (including relevant drug trials, or ethics and social research to do with participating in the Project).

The patient literature is also written so that the discussion can draw potential participants’ awareness (or that of an adult consenting on behalf of a child, or that of a consultee advising in respect of an adult participant who lacks capacity) to key issues or risks from joining the Project, including that:

- For patient groups needing particularly time-sensitive treatments, the results of genomic analysis may not be able to be returned to their clinician in a timeframe that can influence clinical decision-making around treatment for their pertinent condition.
- In general, at this stage in scientific understanding, the significance for health and disease of information revealed by WGS may be relatively uncertain (particularly in the absence of a relevant family history).

This knowledge has improved and is expected to continue to do so, but findings of unknown significance are likely to be generated. These will not be returned to the clinician for discussion with the patient unless there are exceptional circumstances.
• Should a specific and serious risk to the health of a participant’s close family member(s) become apparent via the participant’s pertinent or additional findings (whether these are unexpectedly detected or purposely ‘looked-for’) and where preventive or ameliorative action is possible in regards to these close relatives, the clinical team may seek to contact the relatives to inform them of this in line with standard clinical practice. This may include risks identified after the participant has died.\textsuperscript{xxix}

• Whilst measures will be in place to keep participants’ identity and information confidential, there is an unavoidable, though remote, risk of re-identification through participation.\textsuperscript{xxx}

• The ways in which data security, privacy, access and sharing access to samples and the datasets will be appropriately restricted and monitored.

• Participants can request to see the information held about themselves by the Project and to know the types of third parties who have accessed their data (taking into account all legal obligations under Freedom of Information or Data Protection).

• The process for withdrawing consent to remain in the Project.

• Given the long-term nature of the donation, in future, the samples and information donated may be subject to the application of as-yet unanticipated analyses and investigation because of new knowledge.

\textbf{10.1.2 Giving consent face-to-face}

Generally, consent to participate in the research Project will be part of the clinical conversation (in most instances) by trained members of staff. This discussion will conform to established good consent practice guidelines.\textsuperscript{xxxi} Where possible this should be timed to fit in with scheduled appointments. During the consent discussion regarding research, potential participants and those accompanying them will have the opportunity to ask questions. All potential participants (or people consenting on their behalf) will have been given appropriate time to read and consider the Project’s patient information literature. Literature may be translated by the NHS Genomic Medicine Centres (undertaken forward and back).

In order to record their consent, the potential participant (or the person consenting on their behalf, or the person advising about someone else’s participation) will need to follow the instructions on the consent/ consultee declaration form, tick the boxes, and sign and date the final section, adding their own date of birth as an additional confirmation of their identity.

\textbf{10.1.3 Giving consent at a requested home visit}

It is ideal if all consent and procedures take place in a suitable healthcare environment. If a participant (or the person who might consent on their behalf) requests that the consent discussion takes place in their home (or in another appropriate healthcare setting) it will be a decision for the NHS GMS as to whether this can be provided as an option. If possible, an appropriately trained team member(s) will schedule an appointment convenient to the potential participant(s) and will travel to the agreed location or telephone the patient.

\textbf{10.1.4 Giving consent by post or email}

In appropriate cases, some potential participants may be offered the opportunity to give consent to be part of the research project via the return of a completed consent form to the recruiting clinician or appropriate alternative in the post/via emailed document. A telephone discussion with
a suitably trained person will be offered to them as part of this, to take place at a time suited to the potential participant.

This route to seeking consent will only be used where the clinical team has reason to think that seeking postal consent is an appropriate method for the individual concerned and that consenting face-to-face would inconvenience the patient.

10.1.5 Participants aged 16-18 years
At ages between 16 and 18, it is legally presumed that young people have the ability, or competence to make decisions about their own health care or treatment. When a young person is believed to be competent, consent from those with parental responsibility is not legally required.

On reaching 16 years old, all existing participants will be asked to give their own consent to remain in the programme (unless it is deemed by their medical team that they do not have the capacity to do so at that time). This also applies to those being invited to join the programme at the age of 16.

In most circumstances, young people consenting on their own behalf will be encouraged to involve the person(s) with parental responsibility for them in their decision-making.xxxii Some participants in the Project who join at younger ages, will then reach the age of 16 as participants and at that point will be deemed not to have capacity to consent (or to refuse), their continued participation in the Project on their own behalf. In such cases, the advice of a personal or legal consultee will be sought regarding their continued involvement, in accordance with the provisions of the Mental Capacity Act 2005 for people in research studies in England and Wales.

10.1.6 Participants under the age of 16 years
Where a potential participant is aged under 16 and has not been deemed by their clinical team to have attained the capacity to consent to participation on their own behalf, at least one person with parental responsibility for them, or a guardian, will need to provide consent in order for the minor to participate in the research project.xxxiii The Project will follow appropriate guidance as to the involvement of children in research.xxxiv

Patient information will be available on an age-appropriate basis for children and young people.

All children and young people will be given verbal information about the Project by the person conducting the consenting discussion (who should have experience of working with children/young people, in accordance with the minor’s age and individual circumstances) and will be given opportunities to ask questions.

The person taking the consent should seek the assent of the child as part of the discussion regarding their participation. If the child or young person is capable of assessing the information provided, they will consider their explicit wishes, including their refusal to take part, or desire to withdraw from the study.xxxv

Seeking assent implies that children could have an understanding of the research process and can be informed about what is involved and what they are expected to do. This can be an opportunity for some children to express their opinions and concerns surrounding participation in research, providing them with a formal means to be included or excluded. Where appropriate, the person
taking the consent may wish to offer the child the opportunity to evidence their assent via the completion of an Assent Form. These are provided for the use of 6-15 year olds in the Project.

At the time this discussion takes place, the child or young person may not be in a position to, or may not wish to, complete this form. During any discussion around assent, (regardless of whether an Assent Form is offered or completed), a completed Assent Form will not be considered by the person taking the consent to be the sole or overriding signifier of a child’s willingness to participate in the Project.

If, at an age below 16, a young participant has been deemed competent by a medical team to consent in their own right to remain in the Project, they will be invited to give this consent. The same will apply to young people being invited to join the programme under the age of 16, who have been deemed competent by a medical team to consent in their own right to joining the Project. Young people consenting on their own behalf under the age of 18 will be encouraged to involve their parent or guardian in their decision, as a matter of good practice.

10.1.7 Seeking consent where participation relates to a health emergency

In specific scenarios and in line with the appropriate guidance, consent may be sought to join a person as a proband into the Project while they are in a health emergency, such as in the case of an extreme response to sepsis.

Adults not able to consent for themselves due to an emergency situation

In a health emergency situation, the law in England and Wales allows adults unable to consent for themselves to be recruited into a project without prior advice from a consultee, specifically in regards to that emergency situation. Therefore, and on the advice of the patient’s clinical teams, this project will accept as participants eligible adults who lack capacity due to an emergency situation.

This will include where the timeframe for recruitment does not permit the appointment of a consultee before including the patient into the Project as a participant. This exceptional route to participation is proposed because the potential or actual clinical benefit to be gained by the patient if he or she is included in the Project is likely to depend on their prompt recruitment. Participation may provide clinically relevant information to inform the patient’s care and may also inform the care offered to the patient’s close contacts (for example if the health emergency was caused by an infectious disease).

Recruitment would only take place prior to the appointment of a personal or nominated consultee appointed under the principles of the Mental Capacity Act 2005:

- If it is not reasonably practicable to seek advice from a personal or nominated consultee, and
- The procedure has been approved by an NHS Research Ethics Committee; and
- Provided a consultee is consulted as soon as possible to seek advice on the participant’s likely views and feelings on being included in the Project.

When the patient’s consultee is appointed and consulted, they will be given sufficient information about the Project in an understandable form, to permit their informed advice. They are free to decide to provide this advice or not. Advice given by consultees will be recorded by the person
seeking the recruitment on a Consultee Declaration form (not a consent form). If the adult then recovers their capacity, as soon as possible they will be asked for their consent to participate in the Project on their own behalf.

The clinical team caring for the participant will also offer the participant themselves with information, appropriate to their current state, about the Project and its risks and benefits.\textsuperscript{xi}

**Children who are unable to consent for themselves and in an emergency situation**

In an emergency situation, in England and Wales, the law would allow children and young people to be recruited into the Project specifically in regards to that emergency situation, without prior consent from at least one person with parental responsibility or a guardian. These exceptional circumstances for recruitment would include:

- Prior NHS Research Ethics Committee approval for the Project.
- The same research question could not be assessed by recruiting from a non-emergency environment, and that the research is of potential benefit to the child/young person themselves.\textsuperscript{xii}
- Someone with parental responsibility for the child/young person is informed about the research as soon as possible.
- Their consent (and the child/young person’s assent if they are able to give this) is sought as soon as possible.
- The person seeking the recruitment (who must have previous experience of working with children/young people) makes it clear to the child/young person or their parent (if the child/young person is not competent) that the child/young person can withdraw (or be withdrawn by their parent) at any time and without needing to give any reason.

Adults consenting on behalf of children/young people during an emergency will be informed at the time they give consent, that if and when, the child/young person attains/regains capacity, their consent will be sought for participation as would normally be the case.

**Participants who regain capacity during their participation in the Project**

In all circumstances, any person who attains (or regains) the capacity to decide whether or not to become a participant in the Project will be asked to give us this consent in their own right as soon as is practically possible.

Those acting as consultees for people whilst they were lacking capacity will be informed at the time they gave their advice, that should the person become a participant in the Project and then regain their capacity, that their consent will be sought for participation in their own right.\textsuperscript{xiii}

**Recruiting relatives of the proband in emergency situations**

Adult or child relatives of the proband would not be recruited if they themselves were in a health emergency situation, prior to the appointment of a personal or nominated consultee, unless in exceptional circumstances. Consent would instead be sought for their participation (or advice from a consultee as appropriate) in the normal way, after the health emergency has passed.

**Participants in the Project who lose capacity to consent**
Participants who have joined the Project by giving consent for this in their own right, may afterwards lose their capacity to give their informed consent to take part in treatment or research, or this capacity may become fluctuating.

The consent they gave to become part of the 100,000 Genomes Project, at the time when they had capacity fails at the point it is reported to Genomics England that they cease to have this capacity. Once they become aware of a loss of capacity, the NHS clinical care team should seek to appoint a personal or (if unavailable) a nominated consultee to advise on the patient’s wishes, in line with the Mental Capacity Act Code of Practice published by the Office of the Public Guardian.

In order to safeguard the interests of adult patients who join on the basis of their own consent, Genomics England will ask the NHS GMS to implement a specific check on each participant’s capacity (in cases where a participant has consented to join the Project in their own right), around five years after their consent was first given to join the Project. This routine check should be done via appropriately trained staff on the clinical team at the closest appropriate clinical contact time to that five-year interval, so as not to cause undue burden to the participant or to their clinical team.

Then, for as long as the person remains in the Project under their own consent, the NHS GMS will then be sent a prompt to instigate further routine capacity checks via the clinical team at (approximately) five-yearly intervals. This instruction to re-check from the NHS GMCs will be prompted by a reminder issued from the organisation running the 100,000 Genomes Project. This obligation on Genomics England would also pass to any successor organisation with the responsibility for the ongoing collection of data for the 100,000 Genomes Project. An obligation to participate in this process has also been included in the commissioning of NHS GMS.

Under the Mental Capacity Act as applied in the research setting, we note that there is no legal obligation on researchers to exhaustively ascertain whether or not a participant has lost capacity. For example, if a patient becomes untraceable and falls out of contact with their clinical care team whilst they are also a participant in this programme, it would not be required that Genomics England should require the participant’s clinical team to take measures to seek to restore contact with the patient for the purposes of making this capacity check.

In accordance with the Mental Capacity Act, Genomics England will continue to assume that an individual participant retains capacity, even where a capacity check is inconclusive in relation to that particular individual. Examples of this might be that the participant does not respond to the invitation to this check, or he or she does not wish to take part in this discussion, or if a participant becomes uncontactable to the clinical team.

Capacity may also be assumed where the health care professional tasked to conduct the check by the NHS GMC does not return any results from the check to the NHS GMC (to then return to Genomics England).

However, where results have been ascertained by the NHS GMC as to the capacity of any participant, whether it is via the five yearly capacity check or as determined in the course of routine clinical care, the NHS GMC must pass this information on to Genomics England. The NHS GMC has discretion as to whether or not to pass this information either directly to Genomics England upon receipt, or at the five yearly point that it is requested.
If a clinician wishes to notify the NHS GMC of a participant’s loss of capacity or fluctuating capacity at any intervening point they may of course do so. In normal circumstances this would then prompt the seeking of a personal (or if necessary, nominated) consultee in line with the Mental Capacity Act Code of Practice, published by the Office of the Public Guardian. At the point that Genomics England is informed that the participant has lost capacity, the individual will immediately be removed from the research Project as a participant.

If an adult participant is discovered to have lost capacity, (and where no personal or nominated consultee has been appointed) clinical teams must advise their NHS GMC of this fact. The Genomic Medicine Centre will then inform Genomics England of this, in order for Genomics England to remove that individual as a participant in the 100,000 Genomes Project forthwith. For example, this means that prospective data collection in relation to that individual will cease once this notification is received. However, data already held by Genomics England under prior consent can still be used in accordance with the terms of the consent. In accordance with the principles of the Mental Capacity Act 2005, as applied in the research setting, the affirmative advice of the personal or nominated consultee is then required before the person lacking capacity is able to re-join the Project. If the consultee advises against this, clearly the person may not re-join the Project as a participant.

The advice of the consultee that the person lacking capacity should re-join the Project as a participant will, for example, trigger the resumption of prospective data collection regarding that individual. As with any other participant, this will also permit data collection from recorded information covering any period during which the person was not a participant in the Project.

The advice of the consultee is also required in each instance in relation to any Project activities that both:

- involve an adult participant who is deemed to lack capacity, and are
- physically intrusive, such as the taking of a blood sample (unless this activity is taking place within a health emergency situation, at which point usual principles of clinical care would prevail).

Where the consultee advises that in this instance the participant would not have wanted to undergo the physically intrusive activity that is proposed, then that activity must not be carried out.

In line with the provisions of the Mental Capacity Act as applied in the research setting, should a consultee advise the participant’s clinical team that the participant would have wanted to be withdrawn from the Project (or should the participant recover their capacity and withdraw themselves), this will begin the process of withdrawal without further delay.

A participant’s family may sometimes have a different opinion about their participant relative’s continued participation in the Project after their relative has lost capacity. This will be handled sensitively by the participant’s clinical team, with relatives being encouraged to respect their loved one’s wishes, which were given at the time when they were freely able to act upon these. However, we note that the Project has a legal obligation to carefully consider a request made by a representative to withdraw a participant.
Details for how to withdraw are clearly noted on the Patient Information Sheet and will be publicly available on the Project’s website.

If a participant becomes aware that their capacity to give full and informed consent is likely to lessen, or that their lifespan is likely to be shortened, and they would like to withdraw from the Project whilst they have the capacity to make this decision for themselves, they can withdraw at any time, without being required to give a reason. Participants may or may not also choose to take this opportunity to also inform the clinical team of the names and contact details of individual(s) whom they would like the clinical team to approach as personal consultee(s) in the event that they lose mental capacity. If a participant wishes to ‘lodge’ this information with their care team in circumstances where they are not considering their imminent or future withdrawal, this is also acceptable.

In Wales, the 100,000 Genomes Project is initially set up as a service agreement between Genomics England, Cardiff University, Cardiff & Vale UHB and the Welsh Government. Cardiff & Vale UHB, supported by Cardiff University who secured MRC funding, is leading the operationalisation of the Project and will support any capabilities checks and resulting re-consenting procedures if necessary. Ongoing capability will be assured by the referring clinical geneticist whenever new samples or data for the 100,000 Genomes Project are provided or when due to changes to the scope of the Project, continuing consent has to be ensured. The final structure of the NHS GMC will be determent during the term of the service agreement to allow long term support of the Project, this will be outlined in the service agreement.

10.1.8 Seeking consent to use samples and information regarding a person who is deceased

Project participants who die

Some participants will join the Project giving consent for this in their own right and will then die at a later date, whilst they are still participants in the Project. In line with the Human Tissue Act 2004 (in England, Wales and Northern Ireland) and HTA Code of Practice on Consent, (v14.0, July 2014) the participant’s consent to join the Project would remain valid even after their death. This provision is explicitly outlined to potential participants at the time of consenting. It is in place to maximise medical researchers’ access to deceased participants’ samples and health and personal information, thus maximising the potential for increased medical knowledge far beyond the participant’s own lifespan.

Although the participant’s consent extends beyond their death (e.g. to the collection of recorded health data that emerges after their death or to continued access by approved researchers to the appropriate parts of the participant’s information held by the Project), the participant’s relatives (including those in qualifying relationships) may sometimes have a different opinion after the participant has died. This view will be handled sensitively by the clinical team of the deceased person with relatives being encouraged to respect their relative’s wishes (or in certain cases, to respect the decisions given by the deceased person’s nominated representative/nominee).
We note that the decisions made by a nominee of this kind, appointed by the (now deceased) participant to take decisions after the participant’s death, cannot be overridden by others, even those in qualifying relationships with respect to the deceased person. We note the Project’s legal obligation to consider a request made by a representative to withdraw a deceased participant from inclusion in the project.

It is also explicitly outlined at the time of consenting, that should a specific and serious risk to the health of their close family member(s) become apparent via the participant’s pertinent findings, or additional findings and where treatment exists, then the clinical team are likely to seek to contact these family members, to inform them of this. This may include risks that are identified after the participant has died.

**People who die before giving consent to join the 100,000 Genomes Project: legacy collections**

There may be specific situations where we would like to include samples and available health information from people who have already died, but who are not already participants in this Project. This will generally be in situations where the equivalent information is difficult or impossible to obtain from a living person within the anticipated time frame of the Project. This may include where a deceased person affected by one of the disease groups included in the Project has left biobanked samples or health information as a legacy for use in further medical research.

Legacy collection samples may benefit living patients via inclusion in our Project for example by increasing the number of samples available to researchers within a particular disease group. For example, where a child participant in our Project has a particularly rare form of cancer, other participants with the same condition are unlikely to be found in the time frame of the Project. Biobanked samples and information can therefore be particularly precious to researchers in these situations. We note also that the deceased patients who donated these samples were clearly keen that they should be used to potentially help others after they themselves have died.

The inclusion of relevant legacy samples in the Project will only be considered where likely to add substantially to knowledge and potentially offer benefit to patients. The aims and uses to which the Project would put these samples and information would need to be agreed as being scientifically and ethically in accordance with the broad consent given by the patient who donated them to be bio-banked. This would be agreed by the relevant parties holding the samples and information and by the Genomics England Science Advisory Committee, the Ethics Advisory Committee and the Genomics England Board.

**Adults who die before giving consent to join the Project: seeking consent where a person has (perhaps very recently) died**

Where a person with health problems that may relate to the disease groups in the project, has died without receiving a genetic diagnosis for their condition, and their living relatives might benefit from knowing this, we will consider the inclusion of an appropriate sample and their information into the Project, on the advice of their clinical team.

Where the adult concerned has not left specific directions to cover this eventuality, consent from the appropriate person(s) who are in a ‘qualifying relationship’ to the recently deceased person
at the time of their death will be sought, in order to allow us to include the deceased person in the Project in accordance with the Human Tissue Act.\textsuperscript{xlv} This consent will be sought where:

- The deceased person had not previously specifically consented to join the project before they died (and also, they had not specifically refused, or withdrawn from participation).
- The deceased person’s clinical team would like to include their information and tissue in the Project which will require the use or storage of tissue removed from their body after death.
- Genomics England supports the inclusion of the deceased person’s samples and information into the Project. The consent given in regards to the deceased adult’s participation in this Project should be recorded using the Consent form in respect of a deceased adult and corresponding Participant Information Sheet in respect of a deceased adult.

An adult who has died in England, Wales and Northern Ireland, may have already nominated someone to represent them after their death and to give consent on their behalf. Those close to the deceased will be asked whether this is the case. If there is such a nominated representative, he or she will be asked by an appropriate person from the deceased person’s clinical team to give consent in regard to the deceased person joining the Project. This nominated representative’s consent must not be overridden by other individuals, including those who were in a ‘qualifying relationship’ with the person immediately before their death \textsuperscript{xlvii}

In cases where an adult has recently died, their nominee or the person(s) in a qualifying relationship to the deceased person would be approached in a sensitive and timely manner by the healthcare professional seeking their consent. This trained person will use their clinical judgement to decide whether it is appropriate to make this request. They will explain why the deceased person’s samples and health information might produce pertinent information which may benefit others in similar situations. Research use of the samples taken from their loved one will be discussed, as well as whether these samples were taken as part of their standard clinical care while they were alive, or if necessary, will be gathered by removing a sample (blood or tissue) from their loved one’s body after death, for use in this Project.

Additional looked-for findings will not be offered where the adult in question is deceased.

The healthcare professional seeking this consent is likely to be from the deceased person’s clinical care team, or to be a public health professional who is already communicating with the family around necessary public health actions e.g. after a death from invasive meningococcal infections, identifying ‘close contacts’ and organising appropriate measures for them (such as antibiotics).

**Children who die before giving consent to join the Project:** seeking consent where a child has (perhaps very recently) died or after a stillbirth, miscarriage or termination of pregnancy at any gestation

If in connection with a (suspected) rare genetic disease, a child\textsuperscript{xviii} or a baby has died or he or she was stillborn (i.e. born showing no signs of life and after more than 24 weeks gestation) or where a pregnancy has ended in miscarriage (i.e. at less than 24 weeks gestation) or a termination of pregnancy; it can be very important to the bereaved parents that the reasons for their loss can be sought by doctors and scientists and that they can be informed of any pertinent results.
Some parents may therefore wish for their child’s or foetus’ samples and information to be included into this Project, in order to look for a diagnosis of the condition which has affected them, and perhaps also to inform the parent’s future reproductive decision-making, or that their close family members’. We use ‘child’ as the descriptor in this Protocol and in the patient literature to refer to a deceased child, baby or foetus at any gestation, although the clinical team should take care to use the same terms used by the woman or couple in conversation with them.

Provided that the foetus or child’s health problems may relate to the disease groups in the Project and the clinical team proposing this inclusion feel that the living relatives might benefit from being able to gain further information in connection with their loss, and where an appropriate sample(s) can be gathered, we will consider the inclusion of the sample(s) and related information into the Project, taking into account the advice of the child’s or parent’s clinical team.

The mother or parents may also wish for carrier status testing to be carried out as part of their own participation in the Project e.g. as part of a ‘trio’ in which the parents enter the Project together with the samples and information of the foetus, baby or child who has died. Consent to this carrier testing should be discussed separately as part of the consent process for the parents regarding their own participation and is to be recorded in their own (adult) consent form.

Even where the miscarriage or termination took place when the baby or foetus (depending on the terms the parent wishes to use) was at under 24 weeks’ gestation, the Consent Form for parents of a (deceased) child with a rare genetic disease should be used to record the consent of the mother with legal parental responsibility for their baby or foetus’ samples and information to be included in the project. The mother giving the consent should be asked to read the corresponding Participant Information Sheet for parents of a (deceased) child with a rare genetic disease.

While making a record of the woman’s consent for the inclusion of her baby or foetus (who died at under 24 weeks’ gestation) into the Project would be legally sufficient as an entry into her medical notes, unless for some reason the clinical team find entering her consent into her medical notes to be the only appropriate course of action, we would expect the Consent Form for parents of a (deceased) child with a rare genetic disease to be used to evidence her consent. Taking this separate consent is important because it fits in with existing NHS clinical practice in respect of prenatal diagnosis more generally, and also because it makes it explicit that the woman has consented for the analysis of the foetus or baby’s sample.

Having the two signed Consent Forms (one for the woman herself and one for the foetus or baby) also allows each sample to be tracked individually with its consent which is a standard requirement of this Project, including more straightforwardly facilitating, e.g. withdrawal of the foetus or baby’s samples and information from the Project if requested.

The law requires that where a foetus at above 24 weeks’ gestation, or a baby or child aged under 18 years has died, their remains should be handled in accordance with provisions for gaining consent for the use of the tissue of the deceased. The consent required here needs to be given by an adult with legal parental responsibility for the child who has died. Consent to permit the deceased child’s inclusion in the Project should therefore to be evidenced by this adult using the Consent Form for parents of a (deceased) child with a rare genetic disease and after reading the
corresponding Participant Information Sheet for parents of a (deceased) child with a rare genetic disease.

The consent of one person with parental responsibility is required for a child to be included as a participant in the Project after the child had died (above the age of 24 weeks of gestation), although the consent discussion with the clinical team may involve other family members as appropriate. If no one with parental responsibility for the child is available, then consent will be sought from someone in a qualifying relationship with the child.  

In all cases where a child or baby has recently died, or the pregnancy has recently ended in the miscarriage, stillbirth or termination of pregnancy, the appropriate family member(s) will be approached by the person seeking their consent in a sensitive and timely manner. This healthcare professional should use their clinical judgement to decide when and whether it is appropriate to make this request.

The healthcare professional should explain why the child or foetus’ (blood or tissue) samples and related health information might produce pertinent information which may benefit their family members or may benefit others in similar situations. Ongoing research use of the samples taken will be discussed, as well as whether the samples that will be used by the Project have already been taken as part of standard clinical care, or if necessary, if they will need to be taken by removing a sample from their child’s or baby’s body after his or her death (or by taking a sample from the foetal remains). Additional looked-for findings (about child onset conditions) will not be offered where the child in question is deceased.

If the parents make any specific request in relation to including their child’s samples or information in the Project, that the person taking consent is not sure about, the child’s clinical team or Genomics England should be contacted about this to resolve any outstanding issues, before the consent is taken.

Approaching relatives of the (living) proband to seek consent to participate in the Project

Up-to-date information about the diagnosis and clinical status of other family members can be vital in (for example) determining risks for a proband, particularly when, for example, there appears to be an inherited predisposition to cancer. Accessing this is discussed in ‘Consent and confidentiality in genetic practice’ (2006, Joint Committee on Genomics in Medicine), the principles of which we have referred to in creating the relevant processes. We note that access to information about other family members is governed by the Data Protection Act 1998 and the Access to Health Records Act 1990.

If the (relative) potential participant is an adult, the clinical care team may give the recruited adult participant (who may be the proband or may not be e.g. a proband child’s parent) a recruitment pack to pass on to their relative, if they are willing to take on this role of passing on information. The recruitment pack will contain a letter of introduction, Patient Information Sheet, Consent Form and a postage-prepaid envelope.

The recruited participant may also be provided with an electronic copy of the Patient Information Sheet and Consent Form for forwarding by email to their relative. To indicate their interest in participating in the Project, the relative can return the slip to say:
• They do NOT wish to be part of the Project.
• They agree to be contacted by a team member to find out more about the Project.
• They would like to be part of the Project and give written consent to participate.

The recruitment pack will contain contact details for the proband’s clinical care team and the Project (via Genomics England). Relatives considering joining the Project will have the option to telephone or email for further information. Relatives can then make appointments with the proband’s clinical care team to give blood or saliva samples.

If the potential participant is aged under 16 and lacks capacity to consent (dependent on their circumstances) their parents, guardian or at least one person with parental responsibility for the minor will be provided with the relevant Patient Information Sheet and be asked to consent on behalf of the minor.

10.2 The Process for withdrawing from the Project

The project will be more successful as a resource if few people withdraw once they have joined. However, participants can withdraw at any time without giving a reason. Participants will be reminded that they are welcome to discuss concerns with their clinical team at any time, or to contact Genomics England directly.

Full patient literature including how to withdraw, is available on the Genomics England website.

This lists the various options for withdrawal and provides the contact details for this process. Numbers withdrawing will be monitored by Genomics England, because withdrawal may indicate problems in the consenting or participatory experience.

Participants can withdraw at one of two levels:

‘No further contact’: this means that the Project would no longer contact the participant via their clinical team but would have their permission to retain and use information and samples provided previously, and to obtain and use further information from health records. This level of withdrawal leaves the 100,000 Genomes Project dataset intact and will allow researchers to continue to study disease with the goal of improving knowledge and health.

‘No further use’: in addition to no longer contacting the participant or obtaining further information, any information and samples collected previously would no longer be available to researchers. The Project would destroy samples or return them to the diagnostic archive (although it may not be possible to trace all distributed sample remnants) and would only hold information for archival audit purposes. Such a withdrawal would prevent information about the participant from contributing to further research, but it would not be possible to remove data from research that had already taken place.

In order to allow the clinical team and the project to action the withdrawal, the participant or those who give consent on their behalf, or another appropriate person (in the case of adults lacking capacity to consent of their own behalf), would need to evidence their wish to withdraw from participation in the Project, by requesting and completing the appropriate Withdrawal Form. This
will be either the Full Withdrawal from Participation Form, or Partial Withdrawal from Participation Form.

These forms are available via the participant’s clinical team. The relevant person will be asked how they would like (or would like the participant) to withdraw. The differences between the withdrawal options available will be explained by the person actioning the withdrawal with the patient via the use of a withdrawal form.

As expressed in the withdrawal information, they can choose from either:

Option 1) ‘No further contact’: Partial Withdrawal from participation

Not to be contacted directly by the 100,000 Genomes Project/Genomics England, any further.*

However, previously collected samples from the participant can still be used and collected information will continue to be updated into the Project’s databases from the participant’s records as usual.

It is important to note that a participant’s clinician might want to discuss with them information found in their information or samples, however, which would still be possible under this option.

OR

Option 2) ‘No further use’: Full Withdrawal from participation

Not to be a participant in the 100,000 Genomes Project any further.

Genomics England/The 100,000 Genomes Project will:

• Not contact the participant again.
• Put beyond any further use any samples we hold from the participant.

(It may not be possible to trace all divided parts of their samples that have been distributed to approved third party research projects. Any surplus from these samples is routinely destroyed after the third party’s research is completed.)

• Put beyond any further use the information we hold about the participant (aside from what is required for audit purposes - we need to retain a record that they were once part of the Project and then withdrew).
• Not retrieve anything further from the participant’s health or other records.

* In both options, ‘any further’ means from the point that Genomics England confirms to the participant’s clinician that the withdrawal form has been received by us.

A copy of this form would then be given by the clinical team to:

1) The participant who withdraws.
2) The participant’s clinical team – to be retained locally in the participant’s medical notes.
3) The Project - the clinical team will make Genomics England aware of the withdrawal and send a copy of the withdrawal form electronically for storage.

Participant withdrawal by patient group

Different arrangements are likely to be required by different participant groups to facilitate their withdrawal from the Project.

Withdrawal: Adults who can consent on their own behalf

This group can withdraw on their own behalf by completing the withdrawal form, which their clinical team will then process appropriately. Their withdrawal from the Project is considered to have been actioned from the point that Genomics England confirms to the participant’s clinician that the withdrawal form has been received by us.

Withdrawal: Under 16-year olds deemed to have capacity to consent on their own behalf

A decision from a participant in this patient group to withdraw from participation in the Project, will be treated the same as that of an adult (aged over 16 years old), who is able to consent for themselves.

In normal circumstances, those with parental responsibility or the appropriate legally authorised representative will be encouraged to be involved in this discussion, but the final decision about withdrawal rests with the Gillick competent young person.

The decision to withdraw may be felt to be against the young person’s best interests, but unless the Court of Protection decides that the decision could lead to death or severe permanent injury, which is unlikely to apply here, the young person’s withdrawal of consent must be respected.

Withdrawal: Under 16-year olds who lack capacity to consent on their own behalf

Decisions around withdrawal from this Project on the basis of the child or young person’s dissent will rely on individual circumstances to some degree. The usual practice around participation in research is not always appropriate in the context of this Project. It is the view of the Project that here, it is more appropriate to follow accepted practice in clinical care in relation to refusal of treatment, because the Project offers potential direct clinical benefits to the proband children and young people who participate. The General Medical Council and Royal College of Paediatrics and Child Health advise in relation to children’s participation in medical research, that if a child or young person ‘objects or appears to object in either words or actions’, they will not be required to participate in research.

Decision-making around the clinical care of children or young people who are not Gillick competent should be therefore guided by an assessment of their best interests. It follows from this that it would not be legally determinative if such a child or young person withdrew their assent to participate in the Project (or declined to join the Project). Adult/s with parental responsibility retain the legal power to withdraw (or give) their consent to a child’s participation in the Project.
Children and young people are made aware via the patient information literature for the Project that their views will be taken seriously and if they don’t want to join, or don’t want to continue within the Project, that this dissent will ‘usually’ be accepted.

In practice, this acceptance may depend on the reason that the child or young person gives for seeking to withdraw. Actioning a withdrawal solely on the basis of reluctance expressed to give a blood sample for example, would be likely to entail different considerations than if, say, the child expressed dissent for other reasons.

If a child or young person expresses dissent for reasons which are perhaps not able to be mitigated straightforwardly, and there is no overriding contradictory factor relating to their best interests - especially where direct clinical benefit seems unlikely, then they should be withdrawn from the Project in accordance with their wishes. This should happen even where consent continues from the adult or authority with parental responsibility for that child or young person.

In the case of children or young people who join the Project in order to contribute their information in relation to a proband (such as siblings), the potential for direct clinical benefit to them may be less obvious. In this case, if such a child or young person expresses their wish to withdraw from the Project, this should usually be actioned, on the assumption that benefit may be minimal and withdrawal is not likely to put the health of the sibling child or young person at risk of significant harm.

Withdrawal: Adults who lack capacity to consent on their own behalf

Adults lacking capacity may be recruited to the Project, or they may have joined it under their own consent and then have lost their capacity. In such cases, if the consultee of an adult participant advises that they would wish to be withdrawn, this withdrawal will be actioned, using the ‘Withdrawal Form for a consultee to advise on an adult lacking capacity’, without delay. This is in accordance of the requirements of the Mental Capacity Act (MCA) in a research setting.

If an adult participant who lacks capacity implies or expresses their dissent directly, they will be withdrawn from the Project immediately in line with the MCA and in accordance with General Medical Council guidance which provides specific considerations to be made about the care and treatment of patients who lack capacity.

10.3 Personal insurance and the participants in 100,000 Genomes Project

Under an open-ended agreement between the Department of Health and the Association of British Insurers the results of whole-genome sequencing carried out in the Project are not disclosable to personal life insurers. This is because they are part of an NHS transformation programme with a significant research element. However, insurers have the normal expectation that patients will disclose relevant family history, other non-genetic diagnostic test results and GPs’ reports when applying for new insurance. Under the Genetics and Insurance Concordat and Moratorium, the results of other genetic tests do not need to be disclosed unless the test is for Huntington’s Disease for life insurance and the insured sum is over £500,000. The Concordat and Moratorium has recently been extended from November 2017 until the end of 2019 (see attached letter) from the Department of Health and Association of British Insurers website. We will continue to adhere to the
Concordat and any subsequent agreements and will include in any FAQ or other materials this information for participants.
11 Communications, stakeholder engagement and patient and public involvement
11 Communications, stakeholder engagement and patient and public involvement

11.1 Communications strategy and governance arrangements
Gaining and retaining public trust and confidence is a key element of the 100,000 Genomes Project, both in terms of continued recruitment and wider societal confidence in the use of genomics in medicine. When the NHS Genomic Medicine Service goes live, this will continue to be critical to confidence and take up. Particular issues are privacy and security in relation to data held by Genomics England, access to data services by commercial organisations, such as pharmaceutical companies. The public are particularly concerned about access by insurance companies. Some societal groups have concerns about access by state agencies including police and border agencies.

A communications and stakeholder engagement plan has been developed with communications colleagues in DH and with input from communications leads in NHS England, PHE and HEE. A fortnightly call is held to ensure all partners have sight of, and input into, communications about genomics. Development of a specific engagement plan for the NHS GMS and the GLHs is underway and led by NHS England.

The minister-led National Genomics Board, which consists of specialists from industry, patient support groups, and other key stakeholders will also convene an engagement subgroup to ensure that public and patient involvement remains at the forefront of the future service.

11.2 Communications and stakeholder engagement plan
A communications and stakeholder engagement plan has been developed. Whilst some patient and public involvement (PPI) is specific to Genomics England (for instance, in relation to policies around consent for research and the development of participant literature), there are broader societal concerns about the use of genomics, these relate in particular to commercial use of data and insurance but also how much feedback NHS patients should expect from genomic testing.

These issues require extensive dialogue with the public as genomic medicine is being introduced into routine use by the NHS and continue as a running theme throughout implementation. As part of the future NHS GMS at both a national and local level, Patient and Public involvement and engagement groups and initiatives will play an important and key role in shaping the future NHS service. Genomics England will play a leading role in a coalition of key organisations, to develop, initiate and deliver, this essential public dialogue – acting on the Chief Medical Officer for England’s recommendations in the 2017 ‘Generation Genome’ report.

11.2.1 The Genomics Conversation
The Genomics Conversation was a programme of activities, beginning in 2016 and continued in 2017, led by Genomics England. The aim was to engage the general public and relevant stakeholders in key topics relating to genomic medicine.

The purpose was to begin a dialogue with the wider public and other relevant stakeholders to raise awareness of genomics and to better understand public attitudes to it. It was also important for Genomics England to learn more about potential barriers to embedding genomics into mainstream healthcare. The Genomics Conversation rolled out a broad range of activities, including debates, discussions, presentations, and outreach through social and traditional media.
11.3 Genomics England research projects – seeking the views of patients and the public
In the early stages of the Project, Genomics England undertook a range of work to ensure that potential participant’s views were included in the formulation of the ethical policies submitted for research ethics approval and in the development of patient information. The views of different groups of potential participants (those affected by cancer, rare disease, and those from BAME communities) in relation to ethical issues raised by the 100,000 Genomes Project were sought and findings were published on the Genomics England website (See all reports under ‘patient and public involvement - https://www.genomicsengland.co.uk/library-and-resources/ and the Genomics England Engagement Strategy). Genomics England will continue to engage with these stakeholders. Further to this, each of the 13 currently recruiting NHS Genomic Medicine Centres had dedicated Patient and Public Involvement leads (PPI) who are responsible for engaging with and involving local potential participant groups from diverse backgrounds. It is expected that the future NHS GMS will continue these local PPI activities to shape and inform the service.

Patient and public involvement (PPI) and public engagement
Patient and public involvement is an integral and vital part of the Project. Potential participant views were sought by Genomics England, on key ethical policies relating to consent for rare disease and cancer using a range of experienced, independent specialist market research companies (e.g. Solutions for BAME work, GfK for cancer work, Genetic Alliance UK for rare disease). This feedback was then used in a separate project to inform the design and content of literature. This literature was then extensively tested with potential participants before submission to REC. Literature supporting consent was also tested with professionals involved in the consent process, in order to ensure that there was no divergence in understanding between professionals and patients. Genomics England continues to evaluate and revise its literature, and patient and public materials, for instance including a wide variety of animations and infographics about results.

Bearing in mind the need for equity of access, and mindful particularly of those communities disproportionately affected by rare disease, a programme of work with BAME groups was initiated to understand how best to involve these groups in the project. The rare disease work is complete but work in relation to cancer, remains in progress.

11.4 The National Participant Panel
A Participant Panel has been established. Now in their stride, this 30-strong group has provided invaluable advice on a range of topics for instance in shaping how analysis is monitored, how results are returned and how advice and support should be framed. Participant Panel members have either donated samples to the Project themselves or are carers of participants. They take part in a wide variety of consultative groups, such as the Genomics England Ethics Advisory Committee but most importantly are guardians of the dataset, with representatives on the Access Review Committee. Participants play an important part in every decision made about access to data. This will continue.
12 Appendices
### 12 Appendices

#### Appendix 1 | List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Expansion</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPRD</td>
<td>Clinical Practice Research Datalink</td>
</tr>
<tr>
<td>EAC</td>
<td>(Genomics England) Ethics Advisory Committee</td>
</tr>
<tr>
<td>HEE</td>
<td>Health Education England</td>
</tr>
<tr>
<td>HRA</td>
<td>Health Research Authority</td>
</tr>
<tr>
<td>HSCIC</td>
<td>Health and Social Care Information Centre</td>
</tr>
<tr>
<td>NDPH</td>
<td>Nuffield Department of Population Health</td>
</tr>
<tr>
<td>NGS</td>
<td>Next Generation Sequencing</td>
</tr>
<tr>
<td>NHSE</td>
<td>NHS England</td>
</tr>
<tr>
<td>PHE</td>
<td>Public Health England</td>
</tr>
<tr>
<td>QA</td>
<td>Quality Assurance</td>
</tr>
<tr>
<td>QMUL</td>
<td>Queen Mary University, London</td>
</tr>
<tr>
<td>REC</td>
<td>Research Ethics Committee</td>
</tr>
<tr>
<td>WGS</td>
<td>whole genome sequencing</td>
</tr>
<tr>
<td>CLL</td>
<td>chronic lymphocytic leukaemia</td>
</tr>
<tr>
<td>DPA</td>
<td>Data Protection Act</td>
</tr>
<tr>
<td>FOI</td>
<td>Freedom of Information Act</td>
</tr>
<tr>
<td>ICO</td>
<td>Information Commissioners Office</td>
</tr>
<tr>
<td>FF</td>
<td>Fresh Frozen</td>
</tr>
<tr>
<td>FFPE</td>
<td>Formalin-fixed, paraffin-embedded</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedures</td>
</tr>
<tr>
<td>SMS</td>
<td>Sample Messaging System</td>
</tr>
<tr>
<td>NHS GMS</td>
<td>NHS Genomic Medicine Service</td>
</tr>
</tbody>
</table>
Appendix 2 | WGS Sample Requirements

The sample requirements for WGS are detailed in the Sample Handling Guidance and the sample requirements for the NHS GMS will be an integral part of the test directory.

The research sample requirements are summarised below.

Samples required for participation in project as a rare disease patient and additional optional research samples.

<table>
<thead>
<tr>
<th>Required for diagnosis</th>
<th>Currently considered research samples</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA for WGS and epigenetics (10μg)</td>
<td>RNA-stabilised blood for transcriptomics. (This is more stable than plasma allowing parallel processing of DNA and RNA.)</td>
</tr>
<tr>
<td>Compulsory</td>
<td>Expected where reasonable to target 80% of all probands and affected relatives. NB: Collect more volume in fewer aliquots. Further aliquoting done post-processing.</td>
</tr>
</tbody>
</table>

Samples required for participation in project as a cancer patient and additional optional research samples.

<table>
<thead>
<tr>
<th>Required for diagnosis</th>
<th>Currently considered research samples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germline DNA for WGS and epigenetics (10μg) + Fresh tumour DNA for WGS – (2μg PCR free 500ng needing PCR)</td>
<td>cfDNA at baseline and longitudinal collection using Streck/ EDTA tubes</td>
</tr>
<tr>
<td>Compulsory</td>
<td>Excess tissue for transcriptomics or more DNA</td>
</tr>
</tbody>
</table>

Expected where reasonable. Pre-treatment baseline; post treatment; 3 and 6 month follow up and at recurrence. Optional
N.B. 5mm x 5mm x 2mm of tumour tissue or a 15mm x 2mm core biopsy needle for tumour DNA extraction is advised to achieve a 2µg sample of DNA but this is dependent on the nature of the tumour sample.

**Blood sample volumes – Mandatory for participation**

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Purpose</th>
<th>Collection Strategy</th>
<th>Required tubes</th>
<th>Blood volumes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood for DNA extraction*</td>
<td>WGS &amp; excess for storage</td>
<td>Required for all participants</td>
<td>EDTA</td>
<td>2 x 3-5ml*</td>
</tr>
</tbody>
</table>

* For patients who have had a bone marrow transplant, pre-bone marrow transplant stored DNA extracted from blood or DNA extracted from cultured fibroblasts may be used in place of the Blood EDTA DNA sample. In exceptional circumstances, where considered clinically appropriate and alternative is available DNA extracted from saliva samples may be used.

**Blood sample volumes – Indicative optional samples**

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Purpose</th>
<th>Collection Strategy</th>
<th>Required tubes</th>
<th>Blood volumes</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA - stabilised blood</td>
<td>Transcriptomics</td>
<td>Expected where reasonable for probands &amp; affected relatives. Optional for all unaffected relatives.</td>
<td>PAXgene® blood RNA</td>
<td>2.5ml</td>
</tr>
<tr>
<td>Plasma collected for ctDNA</td>
<td>ctDNA</td>
<td>Optional for all cancer patients at diagnosis; 2-6 weeks post-surgery; at regular intervals post treatment and/or at recurrence.</td>
<td>Streck® or alternative</td>
<td>1-12 x 5mls</td>
</tr>
<tr>
<td>Blood for Plasma</td>
<td>Metabolomics</td>
<td>Optional for all probands &amp; affected relatives. Not required for unaffected relatives.</td>
<td>PST</td>
<td>8ml</td>
</tr>
<tr>
<td>Blood for Serum</td>
<td>Proteomics</td>
<td>Optional for all probands &amp; affected relatives. Not required for unaffected relatives.</td>
<td>SST</td>
<td>8.5ml</td>
</tr>
<tr>
<td></td>
<td>Mandatory for rare disease and cancer</td>
<td>Optional***</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------------------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EDTA</td>
<td>PAXgene® Blood RNA</td>
<td>Streck® or equivalent</td>
<td>PST</td>
</tr>
<tr>
<td></td>
<td>DNA</td>
<td>RNA</td>
<td>ctDNA</td>
<td>Plasma</td>
</tr>
<tr>
<td>Adult (14yrs+)</td>
<td>3-5ml x 2*</td>
<td>&gt;2.5ml</td>
<td>&gt;10mls</td>
<td>&gt;8ml</td>
</tr>
<tr>
<td>3-14 years**</td>
<td>&gt;3ml x 2*</td>
<td>&gt;2.5ml</td>
<td>&gt;3ml</td>
<td>&gt;3ml</td>
</tr>
<tr>
<td>0-3 years**</td>
<td>1-3ml</td>
<td>&gt;2.5ml</td>
<td>&gt;2ml</td>
<td>&gt;1ml</td>
</tr>
</tbody>
</table>

*Sufficient blood needs to be taken to ensure the required quantities of DNA can be extracted (see quantities above 2.0). Quantities can be modified based on local evidence.

**Volumes given for children and adolescents are minimum volumes, wherever possible full collection tubes (vacutainers or paediatric collection tubes) should be obtained of an appropriate size, rather than a partially filled larger tube.

***For optional samples, larger volumes are encouraged. This is because there is a potential diagnostic impact of this testing and transcriptomic tests require repeat runs for technical and sampling validation.
Appendix 3 | Genomics England Governance and Committees

Genomics England Governance and Committees

Genomics England Board 

— Partnership Board (Genomics England & NHSE)

Advisory Committees

Access review committee  Audit Committee  Ethics Advisory Committee*  GeCIP Board*  Participant Panel  Science Advisory Committee*

Independently chaired

Participants only but co-organised

Executive Leadership Team (ELT)

*NHS representation
Appendix 4 | Genomics England Disease List Nomination Process

Please refer to www.genomicsengland.co.uk for further details.
Dear Professor Caulfield

1. **100,000 Genomes Project – disclosure of genome results for insurance purposes**

I am writing in my capacity as the genomics policy lead in the Department of Health to clarify the current policy regarding the use of genetic and genomic information by insurance companies. I am aware that this is potentially a concern for participants in the 100,000 Genomes Project, especially given the novel nature of the project and the long-term storage, analysis and feedback that is envisioned for the project.

The use of genetic test information by insurers is the subject of an agreement between the Government and the Association of British Insurers (ABI). It is set out in the Concordat and Moratorium on Genetics and Insurance last updated and published in 2011. For the purposes of this project the key feature is that the insurers will not require the disclosure of:

"a predictive or diagnostic test result acquired as part of clinical research. To avoid doubt, customers may be asked to disclose details of any symptoms, diagnosis or treatment received outside of the clinical research programme, even if those relate to a condition they found out about through the research programme."

We have agreement from the ABI that the wording used in the Patient Information Sheet is in line with their interpretation of the current policy. The ABI are supportive of the aims of clinical research generally and of the 100,000 Genomes Project particularly. I am sure that they are willing to work with the Department and Genomics England to give specific guidance given the high-profile nature of this project. The initial patient engagement suggests that further detailed Q&A for patients, clinicians and insurance companies may be necessary around the interpretation of the Concordat and Moratorium in relation to the feedback of secondary findings.

The key issues that the agreement covers are the uses of results from clinical genetic tests for highly penetrant late onset disorders. At present, the results of such tests do not need to be disclosed unless they are approved by an independent panel and are for policies over the financial threshold (£500,000 for life insurance). The only approved test is for Huntington’s disease for Life Insurance. Even if the insurance companies were minded to make applications for the other conditions that may be returned as pertinent or incidental findings the timescale is likely to be many months which would give ample notice of a possible need for an amendment of the Patient Information Sheet.

Insurers do expect to be told about symptom, diagnoses or treatment if they request information at the application stage or via a medical report. They may ask for information about family history but many will be willing to consider favourable genetic test results even if they are not approved by the independent panel.

Turning to the longer term, the currently published Concordat and Moratorium states that the agreement will be reviewed in 2014 and will expire in 2017 if not renewed. I am pleased to advise you that we have reached...
agreement with the ABI that the Concordat and Moratorium will be extended until 2019 with a review in 2016. We are in the process of finalising the announcement and intend for this to be made public in the autumn and before recruitment begins via the NHS Genomic Medicine Centres.

Looking beyond 2019 is difficult as the 2016 review will need to be conducted in light of the priorities of the Government of the day. However, it has been a long-standing position in successive administrations that people should not be deterred from accessing healthcare or research opportunities because of concerns about insurance. In the most recent major review of discrimination legislation, in 2008 the Government decided not to extend protection against discrimination on the ground of genetic predisposition because “the existing arrangements for a voluntary moratorium on insurers’ use of predictive genetic test results … along with continued monitoring of the use of genetic testing in the UK should provide sufficient reassurance”.

It has also been the long-standing policy to ensure that the timing of the periodic reviews of the current position always allow at least 3 years before the end of the Concordat and Moratorium in order that the Government has the opportunity to consider alternatives if either party does not wish to continue with the current voluntary agreements.

I hope that this reassures you that the Department is alert to the concerns about the long-term position on genetics and insurance and that we will work with Genomics England and the ABI to ensure that participants concerns are addressed. In doing this, I would remind you that the original policy announcement establishing the 100,000 Genomes Project stressed the importance of ensuring public trust and confidence and said: “To ensure public confidence in matters of confidentiality and access, this work will be monitored by the Chief Medical Officer for England.” As Dame Sally Davies is a Director of Genomics England we will be considering further how she should fulfil this role and how she can address any specific concerns about insurance or other uses of the data in her role advising the Government on medical and scientific matters.

I am copying this letter to Dame Sally Davies and to Felicity Harvey who is the Senior Responsible Officer for the 100,000 Genomes Project.

Please do not hesitate to contact me if I can be of further assistance.

Yours sincerely

[Signature]

Deputy Director: Genomics, Science and Emerging Technologies Health Science & Bioethics Division
Appendix 6 | Consent Process Flows

Detailed consent process maps are included here for reference:

Consent flows zip
Appendix 7 | References


Kalia et al Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics American College of Medical Genetics and Genomics Genetics in Medicine 2017; 19: 249–255


As GMC ‘Good Medical Practice,’ 2013, also notes: See the Declaration of Helsinki and Medicines for Human Use (Clinical Trials) Regulations 2004, which requires parental consent to complement even competent under-16s’ agreement to involvement in trials.


Case law suggests that if a young person has sufficient understanding and intelligence to understand fully what is proposed, and can use and weigh this information in reaching a decision (i.e. often called being 'Gillick- or Fraser- competent'), he or she can give consent to treatment. See Gillick -v- West Norfolk AHA. 3 All Er 402, at 423–4.


HRA definition of consultee: Under the Mental Capacity Act (enforced in England and Wales) before an adult who lacks capacity to give consent can be included in research, the researcher must take reasonable steps to identify someone to consult (a consultee), to determine if participation in research is appropriate. The consultee must be involved in the person’s care, interested in their welfare and must be willing to help. They must not be a professional or paid care worker. They will probably be a family member, but could be another person. A person is not prevented from being a consultee if they are an attorney authorised under a registered Lasting Power of Attorney or are a deputy appointed by the Court of Protection; but that person must not be acting in a professional or paid capacity (for example, person’s solicitor). Available at https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/mental-capacity-act/ (Accessed 7 May 2018)


Health Research Authority, Principles of consent: Adults not able to consent for themselves (England and Wales), Participants regaining capacity during your study. Available at: http://www.hra-decisiontools.org.uk/consent/principles-ALC-EnglandandWales.html (Accessed 7 May 2018)

See Medical Research Council, ‘MRC Ethics Guide: Medical research involving children,’ 2004
Ibid. This states at para 92 that 'if the deceased person has not indicated their consent (or refusal) to post-mortem removal, storage or use of their body or tissue for scheduled purposes, or appointed a nominated representative, then the appropriate consent may be given by someone who was in a 'qualifying relationship' with the deceased person immediately before their death. Those in a qualifying relationship are found in the HT Act in the following order (highest first).

1. spouse or partner (including civil or same sex partner) The HT Act states that, for these purposes, a person is another person's partner if the two of them (whether of different sexes or the same sex) live as partners in an enduring family relationship.
2. parent or child (in this context a child may be of any age and means a biological or adopted child)
3. brother or sister
4. grandparent or grandchild
5. niece or nephew
6. stepfather or stepmother
7. half-brother or half-sister
8. friend of long standing.

It should be noted that the qualifying relatives for adults in Scotland is different and is set out in the Human Tissue (Scotland) Act.

Under the Human Tissue Act 2004 in England, Wales and Northern Ireland, a ‘child’ is defined as being under 18 years old. Under the Human Tissue (Scotland) Act 2006, a ‘child’ is defined as being under 16 years old.

This is because in strictly legal terms, the products of a pregnancy of less than 24 weeks gestation are considered to be the mother’s tissue. (The law does not distinguish between fetal tissue and other tissue from the living; fetal tissue is regarded as the mother’s tissue). For further details, please see the Human Tissue Authority Code of Practice (1) Consent, ‘Consent requirements - Part 2: Tissue from the deceased’. Available at: https://www.hta.gov.uk/sites/default/files/HTA%20Code%20A_1.pdf (Accessed 7 May 2018)
ii British Medical Association ‘Parental responsibility,’ 2008: Guidance from the.

iii See Gillick -v- West Norfolk AHA. 3 All Er 402, at 423–4.

iii General Medical Council, Good Medical Practice (2013), 0-18 years Guidance: Research: point 38

